聯合 狀態

證券交易委員會

華盛頓特區20549

 

表格 10-Q

(標記一)

 

根據1934年證券交易法第13或15(d)節的季度報告

 

截至季度結束日期的財務報告2024年9月30日

根據1934年證券交易法第13條或第15(d)條的過渡報告

 

過渡期從_____到_____

 

委託文件編號:001-39866000-09908

 

tomz_10qimg2.jpg

 

 tomi environmental solutions,inc。

(根據其章程規定的註冊人準確名稱)

 

 

 

(561)

 

59-1947988

(設立或組織的其他管轄區域)

 

(納稅人識別號碼)

 

8430 Spires Way(主要註冊辦公地址,包括郵政編碼)。, Frederick, 馬里蘭州 21701

(總部地址)(郵政編碼)

 

(800) 525-1698

(註冊人電話號碼,包括區號)

 

在法案第12(b)條的規定下注冊的證券:

 

每一類的名稱

 

交易

符號:

 

在其上註冊的交易所的名稱

普通股,每股面值0.01美元

 

TOMZ。

 

納斯達克資本市場資本市場

 

請勾選以下選項以指示註冊人是否在過去12個月內(或在註冊人需要提交此類報告的較短時間內)已提交證券交易法1934年第13或15(d)條所要求提交的所有報告,並且在過去90天內已受到此類報告提交要求的影響。根據交易所法規12b-2中「大型加速文件報告人」,「加速文件報告人」,「小型報告公司」和「新興增長公司」的定義,請勾選發行人是否爲大型加速文件報告人。

 

請在方框內劃勾,以指示註冊人是否已在過去12個月內(或註冊人所需提交此類文件的較短期間內)遞交併張貼了根據規則405條款的電子交互數據文件(本章節第232.405條)。根據交易所法規12b-2中「大型加速文件報告人」,「加速文件報告人」,「小型報告公司」和「新興增長公司」的定義,請勾選發行人是否爲大型加速文件報告人。

 

勾選以下選框,指示申報人是大型加速評估提交人、加速評估提交人、非加速評估提交人、小型報告公司或新興成長型公司。關於「大型加速評估提交人」、「加速評估提交人」、「小型報告公司」和「新興成長型公司」的定義,請參見《交易所法規》第12億.2條。

 

大型加速報告人

加速文件提交人

非加速文件提交人

較小的報告公司

 

 

新興成長公司

 

如果是新興成長型公司,在選中複選標記的同時,如果公司已選擇不使用根據證券交易法第13(a)條提供的任何新的或修訂後的財務會計準則的延長過渡期來符合新的或修訂後的財務會計準則,則表明該公司已選擇不使用根據證券交易法第13(a)條提供的任何新的或修訂後的財務會計準則的延長過渡期來符合新的或修訂後的財務會計準則。☐

 

用複選標記表明註冊人是否爲空殼公司(定義見《交易法》第12b-2條)。是的 沒有 ☒

 

截至2024年10月30日,登記人員持有 20,015,205股份。

 

 

 

  

2024年9月30日結束的第三季度10-Q表格季度報告

 

目錄

      

 

 

 

頁面

 

關於前瞻性陳述的警示性說明

 

3

 

 

 

 

 

 

第一部分

財務信息

 

 

 

 

 

 

 

 

第 1 項

財務報表。

 

4

 

 

 

 

 

 

第 2 項

管理層對財務狀況和經營業績的討論和分析。

 

31

 

 

 

 

 

 

第 3 項

關於市場風險的定量和定性披露。

 

57

 

 

 

 

 

 

第 4 項

控制和程序。

 

57

 

 

 

 

 

 

第二部分

其他信息

 

 

 

 

 

 

 

 

第 1 項

法律訴訟。

 

58

 

 

 

 

 

 

第 1A 項

風險因素。

 

58

 

 

 

 

 

 

第 2 項

未註冊的股權證券銷售和所得款項的使用。

 

58

 

 

 

 

 

 

第 3 項

優先證券違約。

 

58

 

 

 

 

 

 

第 4 項

礦山安全披露。

 

58

 

 

 

 

 

 

第 5 項

其他信息。

 

58

 

 

 

 

 

 

第 6 項

展品。

 

59

 

 

 

 

 

 

簽名

 

60

 

 

 

 

 

展覽索引

 

61

 

 

 
2

目錄

 

前瞻性聲明

 

本季度提交的表格10-Q,或表格10-Q,包含根據1933年《證券法修正案》,或證券法第27A條,1934年《證券交易法修正案》,或交易法第21E條的「前瞻性聲明」,我們打算使這些前瞻性聲明受到其創建的安全港的約束。爲此目的,除了歷史信息外,本表格10-Q中包含的任何聲明均可能被視爲前瞻性聲明。您通常可以將前瞻性聲明識別爲包含「將會」,「會」,「相信」,「期望」,「估計」,「預期」,「打算」,「假設」,「可以」,「可能」,「計劃」,「預測」,「應該」或其否定或類似術語的聲明,旨在識別前瞻性聲明。此外,任何涉及我們未來財務業績預測,業務趨勢或其他未來事件或情況表述的聲明均爲前瞻性聲明。

 

前瞻性聲明涉及已知和未知的風險和不確定性,可能導致實際結果與任何前瞻性聲明中包含的結果大不相同。此處包含的前瞻性聲明基於我們管理層對當前信息的當前預期,涉及多項難以準確預測或無法預測的風險和不確定性,其中許多超出我們的控制範圍。因此,我們的實際結果可能會因各種因素而與任何前瞻性聲明中表達的結果大不相同,並在某些情況下不利影響,其中一些因素在我們於2024年4月1日前向證券交易委員會提交的最近年度報告的「風險因素」欄下列出。讀者應仔細審查這些風險,以及我們不時向證券交易委員會提交的其他文件中描述的額外風險。鑑於此處包含的前瞻性信息中固有的重大風險和不確定性,不應將此類信息的包含視爲我們或任何其他人會實現該等結果的表述,並警告讀者不要過分依賴此類前瞻性信息。除非法律要求,我們不承擔修改此處包含的前瞻性聲明以反映此後事件或情況發生或反映意外事件發生的義務。

 

 
3

目錄

 

第一部分: 財務信息

項目1.基本報表。

 

TOMI ENVIRONMENTAL SOLUTIONS, INC。 

簡明合併資產負債表 

TOMI ENVIRONMENTAL SOLUTIONS, INC。 

 

資產 

 

流動資產:

 

2020年9月30日

2024

(未經審計)

 

 

12月31日

2023

 

現金及現金等價物

 

$809,037

 

 

$2,339,059

 

應收賬款-淨額

 

 

3,146,390

 

 

 

2,429,929

 

其他應收款

 

 

164,150

 

 

 

164,150

 

存貨(注3)

 

 

4,580,115

 

 

 

4,627,103

 

供應商存款(附註4)

 

 

97,488

 

 

 

29,335

 

預付費用

 

 

345,842

 

 

 

371,298

 

流動資產合計

 

 

9,143,022

 

 

 

9,960,874

 

 

 

 

 

 

 

 

 

 

物業和設備淨額(附註5)

 

 

914,156

 

 

 

1,048,642

 

 

 

 

 

 

 

 

 

 

其他資產:

 

 

 

 

 

 

 

 

無形資產淨額(附註6)

 

 

1,108,614

 

 

 

1,123,246

 

經營租賃 - 使用權資產(附註-7)

 

 

417,190

 

 

 

467,935

 

開多期長期應收款- 淨值

 

 

206,240

 

 

 

206,240

 

其他資產

 

 

672,565

 

 

 

550,677

 

其他資產總額

 

 

2,404,609

 

 

 

2,348,098

 

總資產

 

$12,461,787

 

 

$13,357,614

 

 

 

 

 

 

 

 

 

 

負債及股東權益

 

流動負債:

 

 

 

 

 

 

 

 

應付賬款

 

$1,552,223

 

 

$1,267,029

 

應計費用及其他流動負債(注13)

 

 

537,509

 

 

 

675,491

 

長期經營租賃的流動部分

 

 

125,666

 

 

 

115,658

 

總流動負債

 

 

2,215,398

 

 

 

2,058,178

 

 

 

 

 

 

 

 

 

 

長期負債:

 

 

 

 

 

 

 

 

經營租賃長期部分淨額(附註7)

 

 

546,844

 

 

 

642,527

 

應付可轉換票據淨額,扣除未攤銷債務折扣$255,126 和 $301,985 分別爲2024年9月30日和2023年12月31日的基本報表中(附註9)

 

 

2,344,874

 

 

 

2,298,015

 

總長期負債

 

 

2,891,718

 

 

 

2,940,542

 

總負債

 

 

5,107,116

 

 

 

4,998,720

 

 

 

 

 

 

 

 

 

 

承諾和或有事項(附註7和11)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

股東權益:

 

 

 

 

 

 

 

 

累積可轉換A系列優先股;面值 $0.01每股股票價格爲1,000,000 63,750 2024年9月30日和2023年12月31日分別發行並流通的股份數

 

 

638

 

 

 

638

 

累積可轉換B系列優先股;$1,000 stated value指普通股的被指定的價值; 7.5% 累積股利; 4,000 股份已授權; 在2024年6月30日和2023年12月31日分別沒有已發行和流通的

 

 

-

 

 

 

-

 

普通股;每股面值$0.01每股股票價格爲250,000,000 20,015,205和頁面。19,923,955 2024年9月30日和2023年12月31日分別發行並流通的股份數

 

 

200,152

 

 

 

199,240

 

資本公積金

 

 

58,201,140

 

 

 

57,985,245

 

累計赤字

 

 

(51,047,259)

 

 

(49,826,229)

股東權益合計

 

 

7,354,671

 

 

 

8,358,894

 

負債合計和股東權益總計

 

$12,461,787

 

 

$13,357,614

 

 

 

 

 

 

 

 

 

 

附註是這份簡明合併財務報表的不可分割部分。

 

 

 

 

 

 

 

 

 

 
4

目錄

 

 TOMI ENVIRONMENTAL SOLUTIONS, INC。 

 簡明合併利潤表 

          

 

 

截至三個月結算。

 

 

截至……的九個月財務報表

 

 

 

2020年9月30日

 

 

2020年9月30日

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

淨銷售額

 

$2,542,251

 

 

$1,470,019

 

 

$6,669,730

 

 

$5,826,890

 

銷售成本

 

 

981,124

 

 

 

661,087

 

 

 

2,583,419

 

 

 

2,376,442

 

毛利潤

 

 

1,561,127

 

 

 

808,932

 

 

 

4,086,311

 

 

 

3,450,448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

營業費用:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

專業費用

 

 

104,941

 

 

 

207,673

 

 

 

387,267

 

 

 

456,518

 

折舊與攤銷

 

 

69,909

 

 

 

93,929

 

 

 

224,384

 

 

 

273,265

 

銷售費用

 

 

226,593

 

 

 

283,054

 

 

 

881,927

 

 

 

1,160,752

 

迄今爲止,我們的研究和開發費用與AV-101的開發有關。研究和開發費用按照發生的原則確認,並將在收到將用於研究和開發的貨物或服務之前支付的款項資本化,直至收到這些貨物或服務。

 

 

56,338

 

 

 

76,339

 

 

 

185,923

 

 

 

220,587

 

不提供稅前繳納補貼 我們不提供補貼以支付任何已命名高管薪酬或額外福利的個人所得稅。

 

 

44,338

 

 

 

44,355

 

 

 

181,068

 

 

 

188,722

 

總部和行政

 

 

909,906

 

 

 

1,004,618

 

 

 

3,181,304

 

 

 

3,328,726

 

總營業費用

 

 

1,412,025

 

 

 

1,709,968

 

 

 

5,041,873

 

 

 

5,628,570

 

營業收入(損失)

 

 

149,102

 

 

 

(901,036)

 

 

(955,562)

 

 

(2,178,122)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

其他收益(費用):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

利息收入

 

 

3,480

 

 

 

256

 

 

 

15,231

 

 

 

1,264

 

利息費用

 

 

(93,620)

 

 

-

 

 

 

(280,699)

 

 

-

 

其他收入(費用),淨額

 

 

(90,140)

 

 

256

 

 

 

(265,468)

 

 

1,264

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

稅前收益(虧損)

 

 

58,962

 

 

 

(900,780)

 

 

(1,221,030)

 

 

(2,176,858)

所得稅準備(附註15)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

淨利潤

 

$58,962

 

 

$(900,780)

 

$(1,221,030)

 

$(2,176,858)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

每股普通股淨收益(虧損)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

基本

 

$0.00

 

 

$(0.05)

 

$(0.06)

 

$(0.11)

稀釋的

 

$0.00

 

 

$(0.05)

 

$(0.06)

 

$(0.11)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

基本加權平均流通普通股數

 

 

20,015,205

 

 

 

19,823,955

 

 

 

19,984,179

 

 

 

19,818,241

 

攤薄加權平均流通在外普通股數量

 

 

20,096,751

 

 

 

19,823,955

 

 

 

19,984,179

 

 

 

19,818,241

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

附註是合併財務報表的組成部分。

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
5

目錄

   

TOMI ENVIRONMENTAL SOLUTIONS, INC。 

股東權益基本報表摘要

(未經審計) 

 

 

 

 

 

 

 

 

 

截至2024年9月30日止九個月

 

 

 

 

 

 

A類優先股

 

 

普通股

 

 

共計

付費 在MF患者中

 

 

累積的

 

 

總股東權益

 

 

 

股份

 

 

數量

 

 

股份

 

 

數量

 

 

資本

 

 

$

 

 

股東權益

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2024年1月1日的餘額

 

 

63,750

 

 

$638

 

 

 

19,923,955

 

 

$199,240

 

 

$57,985,245

 

 

$(49,826,229)

 

$8,358,894

 

行使認股權證和期權

 

 

 

 

 

 

 

 

 

 

31,250

 

 

 

312

 

 

 

27,188

 

 

 

 

 

 

 

27,500

 

以提供的服務發行普通股

 

 

 

 

 

 

 

 

 

 

60,000

 

 

 

600

 

 

 

44,400

 

 

 

 

 

 

 

45,000

 

股權報酬

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

144,307

 

 

 

 

 

 

 

144,307

 

2024年9月30日結束的九個月的淨(損失)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,221,030)

 

 

(1,221,030)

2024年9月30日的餘額

 

 

63,750

 

 

$638

 

 

 

20,015,205

 

 

$200,152

 

 

$58,201,140

 

 

$(51,047,259)

 

$7,354,671

 

   

 

 

 

 

 

 

 

 

2023年9月30日結束的九個月內的合同餘額

 

 

 

 

 

 

A類優先股

 

 

普通股

 

 

共計

實收資本

 

 

 累積的

 

 

 總股東權益

 

 

 

股份

 

 

數量

 

 

股份

 

 

數量

 

 

資本

 

 

$

 

 

股東權益

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2023年1月1日餘額

 

 

63,750

 

 

$638

 

 

 

19,763,955

 

 

$197,640

 

 

 

57,673,559

 

 

$(46,423,637)

 

$11,448,200

 

除現金報酬外,每位非員工董事都有資格根據我們的2016計劃獲得非合格股票期權和/或限制性股票單位獎勵。根據此政策授予的任何期權均爲非法定期權,自授予之日起十年,或與終止服務相關而提前終止。

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

158,833

 

 

 

 

 

 

 

158,833

 

發行普通股以換取提供的服務

 

 

 

 

 

 

 

 

 

 

60,000

 

 

 

600

 

 

 

50,400

 

 

 

 

 

 

 

51,000

 

2023年9月30日結束的九個月淨(損)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,176,858)

 

 

(2,176,858)

2023年9月30日結餘

 

 

63,750

 

 

$638

 

 

 

19,823,955

 

 

$198,240

 

 

$57,882,792

 

 

$(48,600,495)

 

$9,481,175

 

 

附註是這份簡明合併財務報表的不可分割部分。

 

 
6

目錄

   

 

 

 

 

 

 

截至2024年9月30日三個月的數據

 

 

 

 

 

A類優先股

 

 

普通股

 

 

共計

實收資本

 

 

 累積的

 

 

總股東權益

 

 

 

股份

 

 

數量

 

 

股份

 

 

數量

 

 

註冊資本

 

 

$

 

 

股東權益

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2024年7月1日的餘額

 

 

63,750

 

 

$638

 

 

 

20,015,205

 

 

 

200,152

 

 

$58,201,140

 

 

$(51,106,221)

 

$7,295,709

 

除現金報酬外,每位非員工董事都有資格根據我們的2016計劃獲得非合格股票期權和/或限制性股票單位獎勵。根據此政策授予的任何期權均爲非法定期權,自授予之日起十年,或與終止服務相關而提前終止。

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

爲提供的服務發行普通股

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

2024年9月30日結束的九個月淨利潤

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

58,962

 

 

 

58,962

 

2024年9月30日的餘額

 

 

63,750

 

 

$638

 

 

 

20,015,205

 

 

$200,152

 

 

$58,201,140

 

 

$(51,047,259)

 

$7,354,671

 

   

 

 

 

 

 

 

 

 

截至2023年9月30日三個月的業績

 

 

 

 

 

 

A類優先股

 

 

普通股

 

 

共計

付費 fo@microcaprodeo.com

 

 

累積的

 

 

總股東權益

 

 

 

股份

 

 

數量

 

 

股份

 

 

數量

 

 

註冊資本

 

 

$

 

 

股東權益

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2023年7月1日的餘額

 

 

63,750

 

 

$638

 

 

 

19,823,955

 

 

$198,240

 

 

$57,882,792

 

 

$(47,699,715)

 

$10,381,955

 

2023年9月30日結束的三個月的淨(損失)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(900,780)

 

 

(900,780)

2023年9月30日結餘

 

 

63,750

 

 

$638

 

 

 

19,823,955

 

 

$198,240

 

 

$57,882,792

 

 

$(48,600,495)

 

$9,481,175

 

 

附註是這份簡明合併財務報表的不可分割部分。

 

 
7

目錄

  

TOMI ENVIRONMENTAL SOLUTIONS, INC。

現金流量表簡明綜合報表

(未經審計)

 

 

 

截至9月30日的九個月

 

 

 

2024

 

 

2023

 

經營活動現金流量:

 

 

 

 

 

 

淨利潤(損失)

 

$(1,221,030)

 

$(2,176,858)

調整以調節淨利潤(損失)與經營活動提供的現金淨額之間的差額:

 

 

 

 

 

 

 

 

折舊與攤銷

 

 

224,384

 

 

 

273,265

 

使用權資產攤銷

 

 

117,986

 

 

 

117,986

 

遞延融資費用攤銷

 

 

46,860

 

 

 

-

 

股權補償費用

 

 

144,307

 

 

 

158,833

 

以股份形式發行的股權價值

 

 

45,000

 

 

 

51,000

 

經營資產和負債的變化:

 

 

 

 

 

 

 

 

減少(增加):

 

 

 

 

 

 

 

 

應收賬款

 

 

(716,462)

 

 

404,297

 

庫存

 

 

46,988

 

 

 

14,355

 

預付費用

 

 

25,455

 

 

 

(53,947)

供應商存款

 

 

(68,153)

 

 

357,193

 

其他資產

 

 

(121,888)

 

 

(121,061)

增加(減少):

 

 

 

 

 

 

 

 

應付賬款

 

 

285,194

 

 

 

(546,391)

應計費用

 

 

(137,982)

 

 

(20,758)

客戶存款

 

 

-

 

 

 

(699,732)

租賃負債

 

 

(123,521)

 

 

(119,923)

經營活動產生的淨現金流量

 

 

(1,452,862)

 

 

(2,361,741)

 

 

 

 

 

 

 

 

 

投資活動現金流量:

 

 

 

 

 

 

 

 

購買固定資產和設備

 

 

(104,660)

 

 

(94,295)

投資活動中的淨現金流(應用)

 

 

(104,660)

 

 

(94,295)

 

附註爲簡明合併財務報表的一部分。

 

 
8

目錄

 

tomi environmental solutions, inc.

壓縮的綜合現金流量表 - 繼續

(未經審計)

 

 

 

截至9月30日的九個月

 

 

 

2024

 

 

2023

 

籌資活動現金流量:

 

 

 

 

 

 

股票和權證發行收入

 

$27,500

 

 

 

-

 

籌資活動提供的淨現金

 

 

27,500

 

 

 

-

 

現金及現金等價物的增加(減少)

 

 

(1,530,022)

 

 

(2,456,036)

現金及現金等價物-期初

 

 

2,339,059

 

 

 

3,866,733

 

現金及現金等價物-期末

 

$809,037

 

 

$1,410,697

 

 

 

 

 

 

 

 

 

 

補充現金流量信息:

 

 

 

 

 

 

 

 

支付的利息現金

 

$222,000

 

 

$-

 

 

附註爲簡明合併財務報表的一部分。

 

 
9

目錄

 

TOMI ENVIRONMENTAL SOLUTIONS, INC。

未經審計的縮編合併財務報表附註

 

NOTE 1. 業務描述 Tenax Therapeutics Inc.(「公司」或「Tenax」)最初於1967年以New Jersey公司的形式成立,名稱爲Rudmer,David&Associates,Inc.,隨後將其名稱更改爲Synthetic Blood International,Inc.2008年6月17日,Synthetic Blood International的股東批准了2008年4月28日的《合併協議和計劃》,該協議是Synthetic Blood International與特拉華州公司Oxygen Biotherapeutics,Inc.之間的協議。“(合併協議)合作。“2008年4月17日,Synthetic Blood International成立了Oxygen Biotherapeutics,以參與合併以更改Synthetic Blood International的法定住所,以從New Jersey更改爲Delaware.Certificate of Merger已向New Jersey和Delaware提交,並且合併已於2008年6月30日生效。根據合併計劃,Oxygen Biotherapeutics是倖存的公司,Synthetic Blood International在2008年6月30日發行的每個普通股都會轉換爲一股Oxygen Biotherapeutics普通股。2014年9月19日,公司更改其名稱爲Tenax Therapeutics,Inc。

 

tomi environmental solutions是一家全球的環保母基提供商,通過我們的首席二元離子技術®(BIT™)平台提供消毒和脫臭必需品,我們在該平台下生產、許可、服務和銷售我們的SteraMist®產品系列,包括基於過氧化氫的SteraMist® BIT™的霧化。我們的解決方案和流程環保,因爲我們的脫臭過程中唯一的副產品是氧氣和水,以溼氣的形式存在。我們的解決方案在美國和加拿大被有機列爲可持續綠色產品,幾乎沒有碳足跡。我們的業務分爲四個部門:生命科學、醫療保健、食品安全和商業。

 

在美國國防部的國防高級研究計劃局(DARPA)的國防撥款下研發的,BIT™已在美國環境保護局(EPA)註冊,並以過氧化氫爲唯一活性成分,產生主要是羥基自由基(OH離子)的煙霧。.由SteraMist®品牌代表的iHP™製造的殺菌氣溶膠作爲一種可見的非腐蝕性燃料幣在呈現。

 

我們的產品旨在爲廣泛的商業結構提供服務,包括但不限於醫院和醫療設施,生物安全實驗室,藥品設施,家畜肉類和農產品加工設施,食品安全包括存儲和運輸,高校和研究設施,動物實驗室,其他服務行業包括遊輪,辦公樓,酒店和汽車旅館客房,學校,餐廳,軍工-半導體營房,警察和消防局,監獄和體育設施。我們的產品還被用於單戶住宅和多戶住宅。此外,我們的產品已經被列入EPA的N名單,作爲幫助抗擊COVID-19的產品,並正在積極用於此目的。

 

注2. 重要會計政策總結

 

報告範圍

 

本基本報表系未經審計的中期簡表綜合財務報表,按照美國通用會計準則(「GAAP」)編制,並以美元列示,根據美國證券交易委員會(「SEC」)的規定和法規,由我們編制,未經審計。根據這些規則和法規,按照GAAP編制的財務報表通常包括的某些信息和附註披露已經被壓縮或省略,儘管我們認爲這些披露已足以使所呈現的信息不誤導。

 

這些基本報表反映了所有調整,包括正常遞延調整,據管理層認爲,這些調整對於公允呈現其中所包含的信息是必要的。這些未經審計的簡明合併財務報表應當結合我們截至2023年12月31日的審計財務報表及相關附註進行閱讀,這些內容包含在2024年4月1日已提交給美國證券交易委員會(SEC)的10-K表格的年度報告中(「年度報告」)。我們在編制中期報告時遵循相同的會計政策。本10-Q表格涵蓋的中期期間業績未必能反映整個財年或其他中期期間的業績。

 

合併原則

 

附帶的簡明合併基本報表包括 tomi 及其全資子公司 tomi environmental solutions, inc.,一個內華達州公司的帳戶。所有公司間帳戶和交易在合併中已被消除。

 

截止2024年9月30日的三個和九個月期間,我們的淨利潤爲$59,000 和淨虧損($1,221,000),而截止2024年9月30日爲止的九個月,運營中使用現金爲$1,453,000。截至2024年9月30日,我們大約有$的現金及現金等價物。809,000 在不進行任何其他行動的情況下,公司可能需要額外的流動性以在接下來的12個月內繼續經營。然而,管理層已考慮了其流動性計劃,以繼續將公司作爲一個持續經營的實體,並相信通過管理成本和費用、通過關閉股本和債務發行籌集資本,以及通過增加銷售、政府撥款和其他來源的營收和資金來減輕實體存續疑慮。

 

 
10

目錄

 

帳戶重新分類

 

爲使往年同期基本報表符合當前年度的呈現方式,已進行了某些重新分類。這些重新分類對先前報告的經營業績或財務狀況沒有實質影響。

 

使用估計

 

根據GAAP的規定,編制簡明的綜合基本報表要求我們進行涉及金額、財務報表中披露的預估和假設。實際結果可能與這些估計有重大不同。我們持續評估我們的估計,包括與應收賬款、存貨、金融工具的公允價值、無形資產、無形資產和財產及設備的預期使用壽命、以股票爲基礎的獎勵的公允價值、所得稅和其他擔保責任等相關的估計。我們的估計基於歷史經驗和各種其他被認爲是合理的假設,這些假設的結果構成了對我們資產和負債的賬面價值作出判斷的基礎。

 

公允價值衡量

 

公允價值計量的權威指引定義公允價值爲資產的交易價格或負債的轉讓價格(退出價格),在資產或負債的主要市場或最有利市場上,在計量日期的有序交易中,交易所將收到的或支付的價格。市場參與者是主要市場上的買方和賣方,他們(i)獨立,(ii)知識淵博,(iii)能夠交易,(iv)願意交易。該指引描述了一個基於輸入級別而形成的公允價值層次結構,其中前兩個級別被認爲是可觀察的,最後一個級別爲不可觀察的,可用於衡量公允價值的輸入級別,如下所示:

 

 

一級:

層次2- 除層次1外,還可以間接或直接觀察到的其他輸入,例如類似資產或負債的報價;在非活躍市場上的報價;或其他可以被觀察到的或可通過觀察到的市場數據證實,對於資產或負債的整個期限都具有重要作用的信息。

 

 

二級:

除了一級之外的可觀察輸入,可以直接或間接地觀察到,例如類似資產或負債的報價;不活躍市場中的報價;或者可以通過觀察市場數據明顯證實的資產或負債的其他輸入,貫穿資產或負債的幾乎整個期限。

 

 

三級計量:

不可觀察的輸入,受到很少或根本沒有市場活動支持,並且對於資產或負債的價值非常重要。

 

現金及現金等價物、應收賬款、應付賬款和應計費用的賬面價值大致等於公允價值,因爲這些工具的短期性質。

 

 
11

目錄

 

現金及現金等價物

 

現金及現金等價物包括手頭現金、存放在金融機構的現金以及其他原始期限爲三個月或更短的流動投資。有時,這些存款可能超過保險限額。截至2024年9月30日和2023年12月31日,沒有現金等價物。

 

應收賬款

 

我們的應收賬款通常來自信譽良好的客戶,或對於某些國際客戶,由預付款支持。對於我們向其提供信貸的客戶,我們定期評估他們的地位,並根據需要保留潛在信貸損失的準備金。我們定期審查我們的應收賬款,判斷是否需要形成適當的準備金,這是基於過期帳戶和可能表明帳戶實現疑問的其他因素的分析。經決定無法收取的帳戶餘額,在所有收款手段耗盡,並且恢復潛力被認爲遙不可及後計入準備金。截至2024年9月30日,信貸損失準備金爲$1,271,000,比$ 金額下降1,495,000包銷商在擬議公開發行結束時獲得了25,875股A類普通股。向包銷商發行的股票公允價值爲$。

 

開多期交易應收款項主要是指因銷售商品和提供服務而產生的金額,其合同到期日或實現期超過一年,被確認爲我們合併資產負債表中的"長期應收款項"。

 

存貨

 

Inventories are valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventories consist primarily of finished goods and raw materials.

 

We expense costs to maintain certification to cost of goods sold as incurred.

 

We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories may not be usable.  Our reserve for obsolete inventory was $95,000 as of September 30, 2024 and December 31, 2023.

 

Property and Equipment

 

We account for property and equipment at cost less accumulated depreciation. We compute depreciation using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation for equipment, furniture and fixtures and vehicles commences once placed in service for its intended use. Leasehold improvements are amortized using the straight-line method over the lives of the respective leases or service lives of the improvements, whichever is shorter.

 

Leases

 

We recognize a right-of-use (“ROU”) asset and lease liability for all leases with terms of more than 12 months, in accordance with ASC 842. We utilize the short-term lease recognition exemption for all asset classes as part of our on-going accounting under ASC 842. This means, for those leases that qualify, we will not recognize ROU assets or lease liabilities. Recognition, measurement and presentation of expenses depends on classification as a finance or operating lease.

 

 
12

Table of Contents

 

As a lessee, we utilize the reasonably certain threshold criteria in determining which options we will exercise. Furthermore, our lease payments are based on index rates with minimum annual increases. These represent fixed payments and are captured in the future minimum lease payments calculation. In determining the discount rate to use in calculating the present value of lease payments, we used our incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments.

 

We have also elected the practical expedient to not separate lease and non-lease components for all asset classes, meaning all consideration that is fixed, or in-substance fixed, will be captured as part of our lease components for balance sheet purposes. Furthermore, all variable payments included in lease agreements will be disclosed as variable lease expense when incurred. Generally, variable lease payments are based on usage and common area maintenance. These payments will be included as variable lease expense in the period in which they are incurred.

 

Accounts Payable

 

As of September 30, 2024, one vendor accounted for approximately 56% of accounts payable. As of December 31, 2023, two vendors accounted for approximately 59% of accounts payable.

 

For the three and nine months ended September 30, 2024, two vendors accounted for 53% and 65% of cost of sales, respectively. For the three and nine months ended September 30, 2023, two vendors accounted for 60% and 72% of cost of sales, respectively.

 

Accrued Warranties

 

Accrued warranties represent the estimated costs, if any, that will be incurred during the warranty period of our products. We estimate the expected costs to be incurred during the warranty period and record the expense to the consolidated statement of operations at the date of sale. Our manufacturers assume the warranty against product defects from date of sale, which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results.  As of September 30, 2024, and December 31, 2023, our warranty reserve was $30,000. (See Note 14).

 

Income Taxes

 

Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are, on a more likely than not basis, not expected to be realized in accordance with FASB ASC Topic 740, Income Taxes guidance for income taxes.  Net deferred tax assets have been fully reserved at September 30, 2024 and December 31, 2023.

 

 
13

Table of Contents

 

Net Income (Loss) Per Share

 

Basic net income or (loss) per share is computed by dividing our net income or (loss) by the weighted average number of shares of common stock outstanding during the period presented. Diluted income or (loss) per share is based on the effect from potential issuance of shares of common stock, such as shares issuable pursuant to the exercise of options and warrants and conversions of preferred stock or debentures. The computation of diluted EPS is similar to the computation of basic EPS except that the numerator may have to adjust for any dividends and income or loss associated with potentially dilutive securities that are assumed to have resulted in the issuance of shares of common stock and the denominator may have to adjust to include the number of additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued during the period to reflect the potential dilution that could occur from shares of common stock issuable through a contingent shares issuance arrangement, stock options, warrants, or convertible preferred stock. For purposes of determining diluted earnings per common share, the treasury stock method is used for stock options, and warrants, and the if-converted method is used for convertible preferred stock and convertible debt as prescribed in FASB ASC Topic 260.

 

Potentially dilutive securities for the nine months ended September 30, 2024 consisted of 2,080,000 shares of common stock from convertible debentures, 2,765,846 shares of common stock issuable upon exercise of outstanding warrants, 805,042 shares of common stock issuable upon outstanding stock options and 63,750 shares of common stock issuable upon conversion of outstanding shares of Preferred A stock (“Convertible Series A Preferred Stock”).

 

Potentially dilutive securities for the three months ended September 30, 2023 consisted of 2,773,585 shares of common stock issuable upon exercise of outstanding warrants, 610,500 shares of common stock issuable upon vesting of stock options and exercise and 63,750 shares of common stock issuable upon conversion of outstanding shares of Convertible Series A Preferred Stock.

 

Options, warrants, preferred stock and shares associated with the conversion of debt to purchase approximately 5.7 million and 3.4 million shares of common stock were outstanding on September 30, 2024 and 2023, respectively.

 

The following provides a reconciliation of the shares used in calculating the per share amounts for the periods presented:

   

 

 

For the Three Months Ended September 30,

 

 

 

(Unaudited)

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Net Income (Loss)

 

$58,962

 

 

$(900,780)

Adjustments for convertible debt - as converted

 

 

 

 

 

 

 

 

Net income (loss) attributable to common shareholders

 

$58,962

 

 

$(900,780)

Weighted average number of shares of common stock outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

20,015,205

 

 

 

19,823,955

 

Net income (loss) attributable to common shareholders per share:

 

 

 

 

 

 

 

 

Basic

 

$0.00

 

 

$(0.05)

 

 

 

For the Nine Months Ended September 30,

 

(Unaudited)

 

 

2024

 

 

2023

 

 

 

 

Net Income (Loss)

 

($1,221,030)

 

 

($2,176,858)

 

Net income (loss) attributable to common shareholders

 

($1,221,030)

 

 

($2,176,858)

 

Weighted average number of shares of common stock outstanding:

 

 

 

 

 

 

Basic

 

 

19,984,179

 

 

 

19,818,241

 

Net income (loss) attributable to common shareholders per share:

 

 

 

 

 

 

 

 

Basic and Diluted

 

($0.06)

 

 

($0.11)

 

 

 
14

Table of Contents

 

The following provides a reconciliation of the shares used in calculating the per share amounts for the periods presented:

 

 

 

For the Three Months Ended September 30,

 

 

 

(Unaudited)

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

Net Income (Loss)

 

$58,962

 

 

$(900,780)

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

Basic weighted-average shares

 

 

20,015,205

 

 

 

19,823,955

 

Effect of dilutive securities

 

 

 

 

 

 

 

 

Warrants

 

 

5,908

 

 

 

-

 

Options

 

 

11,888

 

 

 

-

 

Preferred Stock

 

 

63,750

 

 

 

-

 

Diluted Weighted Average Shares

 

 

20,096,751

 

 

 

19,823,955

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to common shareholders per share:

 

 

 

 

 

 

 

 

Diluted

 

$0.00

 

 

$(0.05)

 

The following table sets forth the number of potential shares of common stock that have been excluded from diluted net income per share net (loss) income per share because their effect was anti-dilutive:

 

 

 

For the Three Months Ended September 30,

 

 

 

(Unaudited)

 

 

 

2024

 

 

2023

 

 

 

 

Warrants

 

 

2,734,596

 

 

 

-

 

Convertible Debt 

 

 

 2,080,000

 

 

 

 

 

Options

 

 

573,000

 

 

 

-

 

 

 

 

5,387,596

 

 

 

-

 

 

Note: Warrants, options, convertible debt and preferred stock for the nine months ended September 30, 2024 and for the nine months ended September 30, 2023, are not included in the computation of diluted weighted average shares as such inclusion would be anti-dilutive.

 

 
15

Table of Contents

 

Revenue Recognition

 

We recognize revenue in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations.

 

We must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.

 

Title and risk of loss generally pass to our customers upon shipment. Our customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Shipping and handling costs charged to customers are included in Product Revenues. The associated expenses are treated as fulfillment costs and are included in Cost of Revenues. Revenues are reported net of sales taxes collected from Customers.

 

Disaggregation of Revenue

 

The following table presents our approximate revenues disaggregated by revenue source.

 

Product and Service Revenue

 

 

 

For the three months ended September 30,

(Unaudited)

 

 

 

2024

 

 

2023

 

SteraMist Product

 

$1,766,000

 

 

$953,000

 

Service and Training

 

 

776,000

 

 

 

517,000

 

Total

 

$2,542,000

 

 

$1,470,000

 

 

 
16

Table of Contents

 

Revenue by Geographic Region

 

 

 

For the three months ended September 30,

(Unaudited)

 

 

 

2024

 

 

2023

 

United States

 

$1,886,000

 

 

$1,271,000

 

International

 

 

656,000

 

 

 

199,000

 

Total

 

$2,542,000

 

 

$1,470,000

 

 

Product and Service Revenue

 

 

 

For the nine months ended September 30,

(Unaudited)

 

 

 

2024

 

 

2023

 

SteraMist Product

 

$5,247,000

 

 

$4,501,000

 

Service and Training

 

 

1,423,000

 

 

 

1,326,000

 

Total

 

$6,670,000

 

 

$5,827,000

 

 

Revenue by Geographic Region

 

 

 

For the nine months ended September 30,

(Unaudited)

 

 

 

2024

 

 

2023

 

United States

 

$5,169,000

 

 

$5,001,000

 

International

 

 

1,501,000

 

 

 

826,000

 

Total

 

$6,670,000

 

 

$5,827,000

 

 

Product revenue includes sales from our standard and customized equipment, solution and accessories sold with our equipment. Revenue is recognized upon transfer of control of promised products to customers in an amount that reflects the consideration we expect to receive in exchange for those products.

 

Service and training revenue include sales from our high-level decontamination and service engagements, validation of our equipment and technology and customer training. Service revenue is recognized as the agreed upon services are rendered to our customers in an amount that reflects the consideration we expect to receive in exchange for those services.

 

Costs to Obtain a Contract with a Customer

 

We apply a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling expenses.

 

 
17

Table of Contents

 

Contract Balances

 

As of September 30, 2024, and December 31, 2023, we did not have any unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

 

Arrangements with Multiple Performance Obligations

 

Our contracts with customers may include multiple performance obligations. We enter into contracts that can include various combinations of products and services, which are primarily distinct and accounted for as separate performance obligations.

 

Significant Judgments

 

Our contracts with customers for products and services often dictate the terms and conditions of when the control of the promised products or services is transferred to the customer and the amount of consideration to be received in exchange for the products and services.

 

Equity Compensation Expense

 

We account for equity compensation expense in accordance with FASB ASC 718, “Compensation-Stock Compensation.” Under the provisions of FASB ASC 718, equity compensation expense is estimated at the grant date based on the award’s fair value.

 

The valuation methodology used to determine the fair value of options and warrants issued as compensation during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions including volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk–free interest rates are calculated based on continuously compounded risk–free rates for the appropriate term. The expected term of the Company’s warrants has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” warrants. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its common stock, par value $0.01 (the “Common Stock”) and does not intend to pay dividends on its Common Stock in the foreseeable future. The expected forfeiture rate is estimated based on management’s best assessment.

 

On July 7, 2017, our shareholders approved the Company’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan authorizes the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance units/shares. Up to 2,000,000 shares of Common Stock are authorized for issuance under the 2016 Plan. Shares issued under the 2016 Plan may be either authorized but unissued shares, treasury shares, or any combination thereof. Provisions in the 2016 Plan permit the reuse or reissuance by the 2016 Plan of shares of Common Stock for numerous reasons, including, but not limited to, shares of Common Stock underlying canceled, expired, or forfeited awards of stock-based compensation and stock appreciation rights paid out in the form of cash. Equity compensation expense will typically be awarded in consideration for the future performance of services to us. All recipients of awards under the 2016 Plan are required to enter into award agreements with us at the time of the award, and awards under the 2016 Plan are expressly conditioned upon such agreements. In May 2024, we issued 60,000 shares of Common Stock to members of our Board under the 2016 Plan.

 

 
18

Table of Contents

 

Concentrations of Credit Risk

 

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and cash equivalents. We maintain cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation limit of $250,000 at times during the year.

 

Long-Lived Assets Including Acquired Intangible Assets

 

We assess long-lived assets for potential impairments at the end of each year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the asset. In evaluating long-lived assets for impairment, we measure recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If our long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value. We base the calculations of the estimated fair value of our long-lived assets on the income approach. For the income approach, we use an internally developed discounted cash flow model that includes, among others, the following assumptions: projections of revenues and expenses and related cash flows based on assumed long-term growth rates and demand trends; expected future investments to grow new units; and estimated discount rates. We base these assumptions on our historical data and experience, industry projections, micro and macro general economic condition projections, and our expectations. We had no long-lived asset impairment charges for the three and nine months ended September 30, 2024 and 2023.

 

Advertising and Promotional Expenses

 

Advertising and promotional costs are expensed in the period they are incurred. For the three and nine months ended September 30, 2024, advertising and promotional expenses included in selling expenses were approximately $35,000 and $192,000, respectively. For the same periods in 2023, these expenses were approximately $66,000 and $405,000, respectively.

 

Research and Development Expenses

 

Research and development expenses are expensed in the period they are incurred. For the three and nine months September 30, 2024, these expenses were approximately $56,000 and $186,000, respectively. For the same periods in 2023, research and development expenses were approximately $76,000 and $221,000, respectively.

 

Business Segments

 

We currently have one reportable business segment due to the fact that we derive our revenue primarily from one product iHP (ionized Hydrogen Peroxide) with a variety of applications. A breakdown of revenue is presented in “Revenue Recognition” in Note 2 above.

 

 
19

Table of Contents

 

Recent Accounting Pronouncements

 

Recently issued accounting pronouncements not yet adopted

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

 

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.

 

 
20

Table of Contents

 

NOTE 3. INVENTORIES

 

Inventories consist of the following at (rounded to the nearest thousandth):

 

 

 

September 30,

2024

(Unaudited)

 

 

December 31,

2023

 

Finished Goods

 

$3,709,000

 

 

$3,796,010

 

Raw Materials

 

 

966,000

 

 

 

711,776

 

Inventory Reserve

 

 

(95,000)

 

 

(95,000)

Total

 

$4,580,000

 

 

$4,627,000

 

 

NOTE 4. VENDOR DEPOSITS

 

At September 30, 2024 and December 31, 2023, we maintained vendor deposits of $97,000 and $29,000 respectively, for open purchase orders for inventory.

 

NOTE 5. PROPERTY AND EQUIPMENT

 

Property and equipment consist of the following at:

 

 

 

September 30,

2024

(Unaudited)

 

 

December 31,

2023

 

Furniture and fixtures

 

$458,652

 

 

$364,819

 

Equipment

 

 

2,273,466

 

 

 

2,269,185

 

Vehicles

 

 

66,170

 

 

 

66,170

 

Computer and software

 

 

313,102

 

 

 

306,556

 

Leasehold improvements

 

 

393,381

 

 

 

393,381

 

Tenant Improvement Allowance 

 

 

405,000

 

 

 

405,000

 

Total cost of property and equipment

 

 

3,909,771

 

 

 

3,805,111

 

Less: Accumulated depreciation

 

 

2,995,615

 

 

 

2,756,469

 

Property and Equipment, net

 

$914,156

 

 

$1,048,642

 

 

For the three and nine months ended September 30, 2024, depreciation was $65,031 and $209,751, respectively. For the three and nine months ended September 30, 2023, depreciation was $90,156 and $261,945, respectively. For the three and nine months ended September 30, 2024 and 2023, amortization of tenant improvement allowance was $9,798 and $29,395, respectively and was recorded as lease expense and included within general and administrative expense on the consolidated statement of operations.

 

 
21

Table of Contents

 

NOTE 6. INTANGIBLE ASSETS

 

Intangible assets consist of patents and trademarks related to our Binary Ionization Technology.

We amortize the patents over the estimated remaining lives of the related patents. Trademarks have an indefinite life. Amortization expenses were $4,878 and $14,633 for the three and nine months ended September 30, 2024, respectively. Amortization expense was $3,773 and $11,312 for the three and nine months ended September 30, 2023, respectively.

 

Definite life intangible assets consist of the following:

 

 

 

September 30,

2024

(Unaudited)

 

 

December 31,

2023

 

Intellectual Property and Patents

 

$3,196,396

 

 

$3,196,396

 

Less: Accumulated Amortization

 

 

2,918,646

 

 

 

2,904,013

 

Patents, net

 

$277,750

 

 

$292,383

 

 

Indefinite life intangible assets consist of the following:

 

Trademarks

 

 

830,864

 

 

 

830,863

 

 

Total Intangible Assets, net

 

$1,108,614

 

 

$1,123,246

 

 

Approximate future amortization is as follows (rounded to nearest thousandth):

 

Year Ended:

Amount

October 1 – December 31, 2024

$5,000

December 31, 2025

20,000

December 31, 2026

20,000

December 31, 2027

20,000

December 31, 2028

20,000

Thereafter

193,000

Total

$278,000

 

NOTE 7. LEASES

 

In April 2018, we entered into a 10-year lease agreement for a new 9,000-square-foot facility that contains office, warehouse, lab and research and development space in Frederick, Maryland. The lease agreement commenced in December 2018 when the property was ready for occupancy. The agreement provided for annual rent of $143,460, an escalation clause that increases the rent 3% year over year, a landlord tenant improvement allowance of $405,000 and additional landlord work as discussed in the lease agreement. We took occupancy of the property on December 17, 2018, and the lease was amended in March 2019 to provide for a 4-month rent holiday and a commencement date of April 1, 2019. A 7% discount rate was determined using our incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.

 

 
22

Table of Contents

 

The balances for our operating lease where we are the lessee are presented as follows within our condensed consolidated balance sheet:

 

Operating leases:

 

September 30,

2024

(Unaudited)

 

 

December 31,

2023

 

 

Assets:

 

 

 

 

 

 

Operating lease right-of-use asset

 

$417,190

 

 

$467,935

 

Liabilities:

 

 

 

 

 

 

 

 

Current Portion of Long-Term Operating Lease

 

$125,666

 

 

$115,658

 

Long-Term Operating Lease, Net of Current Portion

 

 

546,844

 

 

 

642,527

 

Total Right of Use Liability

 

$672,510

 

 

$785,185

 

 

The components of lease expense are as follows and are included within general and administrative expense on our condensed consolidated statement of operations:

 

 

 

For the Three Months Ended September 30, 2024

(Unaudited)

 

 

For the Three Months Ended September 30, 2023

(Unaudited)

 

 

 

 

 

 

 

 

Operating lease expense

 

$39,329

 

 

$39,329

 

 

 

 

For the Nine Months Ended September 30, 2024

 

 

For the Nine Months Ended September 30, 2023

 

 

 

 (Unaudited)

 

 

 (Unaudited)

 

 

 

 

 

 

 

 

Operating lease expense

 

$117,986

 

 

$117,986

 

 

Other information related to leases where we are the lessee is as follows:

 

 

 

September 30,

2024

(Unaudited)

 

 

December 31,

2023

 

 

Weighted-average remaining lease term:

 

 

 

 

 

 

Operating leases

 

4.25 years

 

 

5.00 years

 

 

 

 

 

 

 

 

Discount rate:

 

 

 

 

 

 

Operating leases

 

 

7.00%

 

 

7.00%

 

 
23

Table of Contents

 

Supplemental cash flow information related to leases where we are the lessee is as follows:

 

 

 

For the Three Months Ended September 30, 2024

 (Unaudited)

 

 

For the Three Months Ended September 30, 2023

 (Unaudited)

 

Cash paid for amounts included in the measurement of lease liabilities:

 

$41,577

 

 

$40,366

 

   

 

 

For the Nine Months Ended September 30, 2024

 

 

For the Nine Months Ended September 30, 2023

 

 

 

(Unaudited)

 

 

 Unaudited)

 

Cash paid for amounts included in the measurement of lease liabilities:

 

$123,521

 

 

$119,923

 

 

As of September 30, 2024, the maturities of our operating lease liability are as follows:

 

Year Ended:

 

Operating Lease

 

October 1 – December 31, 2024

 

$41,577

 

December 31, 2025

 

 

170,051

 

December 31, 2026

 

 

175,153

 

December 31, 2027

 

 

180,408

 

December 31, 2028

 

 

185,819

 

Thereafter

 

 

33,751

 

Total minimum lease payments

 

 

786,759

 

Less: Interest

 

 

114,249

 

Imputed value of lease obligations

 

 

672,510

 

Less: Current portion

 

 

125,666

 

Long-term portion of lease obligations

 

$546,844

 

 

NOTE 8. CLOUD COMPUTING SERVICE CONTRACT

 

In May 2020, we entered into a cloud computing service contract with a vendor. The contract provides for annual payments in the amount of $30,409 and has a term of 5 years. The annual contract payments are capitalized as a prepaid expense and amortized over a twelve-month period.

 

We have incurred implementation costs of $66,857 in connection with the cloud computing service contract which have been capitalized in prepaid expenses and other assets as of September 30, 2024. In accordance with ASU No. 2018-15, such implementation costs are being amortized over the remaining contract terms beginning January 1, 2021, which was when the cloud-based service contract was placed in service. Amortization expense for the three and nine months ended September 30, 2024 and 2023 were $3,766 and $11,297, respectively.

 

 
24

Table of Contents

 

NOTE 9. CONVERTIBLE DEBT

 

In October and November 2023, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (collectively, the “Investors”) pursuant to which we agreed to sell and issue to the Investors in a private placement transaction (the “Private Placement”) in one or more closings up to an aggregate principal amount of $5,000,000 of Convertible Notes (the “Notes”). In October and November 2023, we sold and issued an aggregate of $2,600,000 of Notes that are convertible into 2,080,000 shares of common stock at a conversion price of $1.25 per share. As of December 31, 2023, we issued and sold an aggregate of $2,600,000 of Notes to certain Investors pursuant to the SPA.

 

The Notes mature and are due on the fifth anniversary of the issuance date in October and November of 2028. The Notes bear simple interest at a rate of 12% per annum, payable in equal monthly installments. The Notes are convertible into shares of our Common Stock, at the option of the holder, at an initial conversion price of $1.25 per share, which shall not exceed $1.55 per share. In addition, we can require Investors to convert the Notes at the then current conversion price at any time after 90 days from the issue date if the Common Stock has a closing bid price of $1.55 per share or higher on any twenty (20) days within a thirty (30) day period of consecutive trading days, or if a “fundamental change” occurs (as defined in the Securities Purchase Agreement). The Notes are unsecured and senior to other indebtedness subject to certain exceptions. Interest expense related to the Notes for the three and nine months ended September 30, 2024 were $78,000 and $234,000, respectively. Interest expense related to the Notes for the three and nine months ended September 30, 2023 were $0 and $0, respectively

 

Amortization of deferred financing costs were $15,620 and $46,860 for the three and nine months ended September 30, 2024, respectively which has been included with interest expense on the statement of operations, amortization of deferred financing costs were $0 and $0 for the three and nine months ended September 30, 2023, respectively.

 

Convertible notes consist of the following at:

 

 

 

September 30,

 

 

 

 

 

2024

 

 

December 31,

 

 

 

    (Unaudited)

 

 

2023 

 

 

 

 

 

 

 

 

Convertible notes

 

$2,600,000

 

 

$2,600,000

 

Less: Debt issuance costs

 

 

(312,399)

 

 

(312,398)

Accumulated amortization

 

 

57,273

 

 

 

10,413

 

Convertible notes, net

 

$2,344,874

 

 

$2,298,015

 

 

 
25

Table of Contents

 

NOTE 10. SHAREHOLDERS’ EQUITY

 

Our Board of Directors (the “Board”) may, without further action by our shareholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of such preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up by us before any payment is made to the holders of our Common Stock. Furthermore, the Board could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our Common Stock.

 

Convertible Series A Preferred Stock

 

Our authorized Convertible Series A Preferred Stock, $0.01 par value, consists of 1,000,000 shares. At September 30, 2024 and December 31, 2023, there were 63,750 shares issued and outstanding. The Convertible Series A Preferred Stock is convertible at the rate of one share of common stock for one share of Convertible Series A Preferred Stock.

 

Convertible Series B Preferred Stock

 

Our authorized Convertible Series B Preferred Stock, $1,000 stated value, 7.5% cumulative dividend, consists of 4,000 shares. At September 30, 2024 and December 31, 2023, there were no shares issued and outstanding. Each share of Convertible Series B Preferred Stock may be converted (at the holder’s election) into two hundred shares of our Common Stock.

 

Common Stock

 

In January 2023, we issued 60,000 shares of Common Stock valued at approximately $51,000 to members of our Board pursuant to our equity plan (see Note 12). 

 

In May 2024, we issued 60,000 shares of Common Stock valued at approximately $45,000 to members of our Board pursuant to our equity plan (see Note 12). 

 

Stock Options

 

In May 2024, we issued options to purchase 225,000 shares of Common Stock to officers at an exercise price of $0.75 per share pursuant to an employment agreement. The options were valued at $144,307 and have a contractual term of 10 years. We utilized the Black-Scholes model to fair value the options received by Officers with the following assumptions: volatility, 125%; expected dividend yield, 0%; risk free interest rate, 4.35%; and a contractual term of 10 years. The grant date fair value of each share of Common Stock underlying the options was $0.64.

 

 
26

Table of Contents

 

The following table summarizes stock options outstanding as of September 30, 2024 and December 31, 2023:

 

 

 

September 30,

2024

 

 

December 31,

 

 

 

(Unaudited)

 

 

2023

 

 

 

Number of Options

 

 

Weighted Average Exercise Price

 

 

Number of Options

 

 

Weighted Average Exercise Price

 

Outstanding, beginning of period

 

 

617,542

 

 

$1.38

 

 

 

413,000

 

 

$1.65

 

Granted

 

 

225,000

 

 

 

0.75

 

 

 

217,042

 

 

 

0.82

 

Exercised

 

 

(31,250)

 

 

0.88

 

 

 

-

 

 

 

-

 

Expired

 

 

(6,250)

 

 

0.80

 

 

 

(12,500)

 

 

-

 

Outstanding, end of period

 

 

805,042

 

 

$1.23

 

 

 

617,542

 

 

$1.38

 

 

Options outstanding and exercisable by price range as of September 30, 2024 were as follows:

 

Outstanding Options

 

 

Average

 

 

Exercisable Options

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Remaining

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Contractual

 

 

 

 

 

Average

 

Range

 

 

Number

 

 

Life in Years

 

 

Number

 

 

Exercise Price

 

$

0.71

 

 

 

7,042

 

 

 

3.31

 

 

 

7,042

 

 

$0.71

 

$

0.75

 

 

 

225,000

 

 

 

9.38

 

 

 

225,000

 

 

$0.75

 

$

0.80

 

 

 

21,250

 

 

 

1.20

 

 

 

21,250

 

 

$0.80

 

$

0.85

 

 

 

210,000

 

 

 

8.08

 

 

 

210,000

 

 

$0.85

 

$

0.96

 

 

 

12,500

 

 

 

0.02

 

 

 

12,500

 

 

$0.96

 

$

1.12

 

 

 

270,000

 

 

 

8.06

 

 

 

270,000

 

 

$1.12

 

$

1.93

 

 

 

10,500

 

 

 

3.06

 

 

 

10,500

 

 

$1.93

 

$

2.16

 

 

 

5,000

 

 

 

1.00

 

 

 

5,000

 

 

$2.16

 

$

4.40

 

 

 

12,500

 

 

 

2.05

 

 

 

12,500

 

 

$4.40

 

$

7.06

 

 

 

31,250

 

 

 

1.75

 

 

 

31,250

 

 

$7.06

 

 

 

 

 

 

805,042

 

 

 

7.64

 

 

 

805,042

 

 

$1.23

 

 

Common Stock Warrants

 

The following table summarizes the outstanding common stock warrants as of September 30, 2024 and December 31, 2023:

 

 

 

September 30, 2024

 

 

December 31, 2023

 

 

 

(Unaudited)

 

 

Weighted Average

Exercise Price

 

 

Number of Warrants

 

 

Weighted Average

Exercise Price

 

Outstanding, beginning of period

 

 

2,772,097

 

 

$2.25

 

 

 

2,792,335

 

 

$2.25

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Expired 

 

 

(6,250)

 

 

(1.12)

 

 

(20,238)

 

 

(1.11)

Outstanding, end of period

 

 

2,765,846

 

 

$2.26

 

 

 

2,772,097

 

 

$2.25

 

 

 
27

Table of Contents

 

Warrants outstanding and exercisable by price range as of September 30, 2024 were as follows: 

 

Outstanding Warrants

 

 

 

 

Exercisable Warrants

 

Exercise Price

 

 

Number

 

 

Average Weighted

Remaining Contractual

Life in Years

 

 

Number

 

 

Weighted Average

Exercise Price

 

$

0.64

 

 

 

31,250

 

 

 

9.14

 

 

 

31,250

 

 

$0.64

 

$

0.80

 

 

 

125,000

 

 

 

9.33

 

 

 

125,000

 

 

$0.80

 

$

0.96

 

 

 

442,708

 

 

 

8.14

 

 

 

442,708

 

 

$0.96

 

$

1.20

 

 

 

156,250

 

 

 

0.34

 

 

 

156,250

 

 

$1.20

 

$

1.68

 

 

 

1,434,721

 

 

 

1.99

 

 

 

1,434,721

 

 

$1.68

 

$

2.18

 

 

 

172,167

 

 

 

1.99

 

 

 

172,167

 

 

$2.18

 

$

4.00

 

 

 

28,750

 

 

 

5.57

 

 

 

28,750

 

 

$4.00

 

$

6.95

 

 

 

375,000

 

 

 

6.01

 

 

 

375,000

 

 

$6.95

 

 

 

 

 

 

2,765,846

 

 

 

3.88

 

 

 

2,765,846

 

 

$2.26

 

 

There were no unvested warrants outstanding as of September 30, 2024.

 

NOTE 11. COMMITMENTS AND CONTINGENCIES

 

Legal Contingencies

 

We may become a party to litigation in the normal course of business. In the opinion of management, there are no legal matters involving us that would have a material adverse effect upon our financial condition, results of operations or cash flows. In addition, from time to time, we may have to file claims against parties that infringe on our intellectual property.

 

Product Liability

 

As of September 30, 2024 and December 31, 2023, there were no claims against us for product liability.

 

NOTE 12. CONTRACTS AND AGREEMENTS

 

Director Compensation

 

In January 2023, we increased the annual fee to non-employee members of our Board to $48,000, to be paid in cash on a quarterly basis, with the exception of the audit committee chairperson, whose annual fee was increased to $54,600, also to be paid in cash on a quarterly basis. Non-employee Director compensation also includes the annual issuance of our Common Stock.

 

For the nine months ended September 30, 2023, we issued an aggregate of 60,000 shares of Common Stock that were valued at approximately $51,000 to members of our Board.

 

For the nine months ended September 30, 2024, we issued an aggregate of 60,000 shares of Common Stock that were valued at approximately $45,000 to members of our Board.

 

 
28

Table of Contents

 

NOTE 13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

 

Accrued expenses and other current liabilities consisted of the following at:

 

 

 

September 30,

2024

(Unaudited)

 

 

December 31,

2023

 

Commissions

 

$191,481

 

 

$200,837

 

Payroll and related costs

 

 

204,345

 

 

 

201,009

 

Director fees   

 

 

37,650

 

 

 

37,650

 

Sales Tax Payable  

 

 

4,916

 

 

 

5,707

 

Accrued warranty (Note 14)

 

 

30,000

 

 

 

30,000

 

Allowance for Sales Returns

 

 

0

 

 

 

128,390

 

Other accrued expenses

 

 

69,117

 

 

 

71,898

 

Total

 

$537,509

 

 

$675,491

 

 

NOTE 14. ACCRUED WARRANTY

 

Our manufacturers assume the warranty against product defects from date of sale, which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results. The warranty is generally limited to a refund of the original purchase price of the product or a replacement part. We estimate warranty costs based on historical warranty claim experience.

 

The following table presents warranty reserve activities at:

 

 

 

September 30,

2024

 (Unaudited)

 

 

December 31,

2023

 

Beginning accrued warranty costs

 

$30,000

 

 

$68,000

 

Provision for warranty expense

 

 

11,066

 

 

 

26,911

 

Settlement of warranty claims

 

 

(11,066)

 

 

(64,911)

Ending accrued warranty costs

 

$30,000

 

 

$30,000

 

 

 
29

Table of Contents

 

NOTE 15. INCOME TAXES

 

For the three and nine months ended September 30, 2024 and 2023, our provision for income tax was $0. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits, which are, on a more likely than not basis, not expected to be realized in accordance with FASB ASC Topic 740, Income Taxes. As of September 30, 2024 and December 31, 2023, we recorded a valuation allowance of $7,851,000 and $7,539,000, respectively for the portion of the deferred tax assets that we do not expect to be realized. Management believes that based on the available information, it is more likely than not that the remaining U.S. deferred tax assets will not be realized, such that a full of 100% valuation allowance is required against U.S. deferred tax assets. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

 

NOTE 16. CUSTOMER CONCENTRATION

 

One customer accounted for 12% of net revenue for the three months ended September 30, 2024. Three customers accounted for 55% of net revenue for the three months ended September 30, 2023.

 

One customer accounted for 18% of our revenue for the nine months ended September 30, 2024. Three customers accounted for 32% of our revenue for the nine months ended September 30, 2023.

 

As of September 30, 2024, two customers accounted for 24% of our gross accounts receivable.  As of December 31, 2023, two customers accounted for 27% of our gross accounts receivable.

 

 
30

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (this “MD&A”) and other parts of this Quarterly Report on Form 10-Q (“Form 10-Q”) contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Forward-looking statements are not guaranteeing future performance and the TOMI Environmental Solutions, Inc. (the “Company,” “TOMI,” “we,” and “our”) actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “Annual Report”) under the heading “Risk Factors.” The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

 

Unless otherwise stated, all information presented herein is based on the Company’s fiscal calendar, and references to years, quarters, months or periods refer to the Company’s fiscal years ended in December and the associated quarters, months and periods of those fiscal years. Each of the terms the “Company” and “TOMI” as used herein refers collectively to TOMI Environmental Solutions, Inc. unless otherwise stated.

 

The following MD&A should be read in conjunction with the Annual Report filed with the SEC and the condensed consolidated financial statements and accompanying notes included in Part I, Item 1 of this Form 10-Q.

 

Quarterly Highlights

 

Business Update

 

We continue to see improved financial results as the third quarter marks our second consecutive profitable quarter in our 2024 calendar year. The improved financial results are largely due to higher revenue, improved gross profit margins, and strategic reductions in operating expenses. We also were cash flow positive in the third quarter due to the improved turnover in our accounts receivable and lower monthly outgoing cash expenditures with management’s spending cuts. We continue to expand our customer base and secured significant agreements and new partnerships.

 

Revenue for the third quarter 2024 was $2,542,000 which represents $1,072,000 or 73% growth compared to the third quarter of the prior year. The higher revenue was attributable to increased demand for our mobile units and higher iHP service revenue.

 

For the nine months ended September 30, 2024, TOMI reported a 14.5% increase in revenue, amounting to $6,670,000, compared to the same period in 2023. This growth was primarily driven by higher mobile equipment sales, with our mobile SteraMist equipment increasing 90% in 2024 compared to 2023.

 

For the nine months ended September 30, 2024, our international revenue grew by 82%, driven by new customers in Canada, South Africa, and India, compared to the same period in 2023.

 

Our total recognized revenue and backlog for the nine months ended September 30, 2024 amounted to $7,200,000, consisting of approximately $6,700,000 in recognized revenue and a sales backlog of approximately $500,000 at the end of September 2024.

 

Our gross profit margins for the three months ended September 30, 2024 were 61.4%, compared to 55% in the same prior year period. The improved gross profit margins were attributable to our product mix in sale and the increased demand for our mobile equipment.

 

Our General and Administrative expenses declined by $148,000 or 4% during the first nine months ended September 30, 2024 compared to the same period in 2023. This decrease was primarily due to operating expense controls, lower executive compensation and a reduction in consultant fees.

 

 
31

Table of Contents

 

During the third quarter, management continued cost reduction initiatives that lowered our operating expenses by 10% compared to the same period last year. Additionally, our operating expenses in the third quarter of 2024 decreased by 19% compared to the second quarter of 2024 as a result of our cost-cutting measures.

 

We continue to pursue innovative solutions and new markets for our versatile and environmentally friendly SteraMist iHP technology.

 

During 2024, the service decontamination sector experienced shifts among key competitors, resulting in an increased volume of leads for our company. On March 7, 2024, we announced the expansion of SteraMist iHP Corporate Service contracts through the addition of new strategic partners. This growth accelerated through the second quarter and has seen substantial momentum in the third quarter, with record-breaking revenue. We continue to support key clients, including Pfizer, Inc. and Thermo Fisher Scientific facilities, while successfully onboarding new customers such as Integra life sciences, Curia, and multiple smaller engagements within the Food Safety sector. These new relationships are expected to drive future sales across both capital equipment and routine service contracts. The addition of these customers further solidifies iHP’s position as a market leader in advanced decontamination solutions, serving corporate clients across life sciences and adjacent industries.

 

To enhance our market presence in the western United States, we formed a strategic partnership with EMAQ in the second half of the year. EMAQ has made a significant investment exceeding $1,000,000 in SteraMist iHP equipment and will act as our regional partner to expand iHP services in this area. This collaboration is expected to drive substantial growth in solution sales, leveraging our razor-and-blade business model—where SteraMist delivery systems represent the razor, and our proprietary BIT Solution serves as the razor blade that is designed to generate ongoing revenue. The partnership is progressing well, with both companies effectively combining strengths and resources to build business and expand opportunities.

 

Demand for our CES systems continues to grow as our portfolio of systems that are being built. In February 2024, we announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company. The contracted iHP Custom Engineered System (CES) is valued at approximately $600,000. This system, featuring six applicators, will be integrated into a clinical suite, and is expected to be fully qualified and in use by the end of the 2024 year.

 

This year we received an order for our CES system with a global leader in advanced laboratory services. This customer purchased two additional Environment Systems to their original fleet of two Environment Systems and a seven (7) applicator iHP Custom Engineered System (CES).

 

With the successful completion of each project, our iHP technology is rapidly gaining popularity as the preferred decontamination solution for pharmaceutical and biotech companies. Further, as we continue to install our technology in new CES projects, the product line evolves into a comprehensive turnkey solution.

 

We believe our industry is experiencing a shift towards modular cleanroom requirements which may benefit our business operations. The adaptability and efficiency offered by our iHP technology align perfectly with the changing needs of cleanroom setups. This trend allows us to capitalize on the increasing demand for flexible and scalable cleanroom solutions, further enhancing the relevance and value of our products within the industry.

 

 
32

Table of Contents

 

We believe our growing portfolio of CES systems will give us a competitive edge in the Life Sciences market segment, improving our brand recognition and creating new business and sales opportunities. In addition, after our installed CES projects are fully qualified and established for use, and as our portfolio grows, we anticipate this will have a positive impact on our long-term recurring BIT solution sales thus providing the potential to enhance our operating margins, further strengthening our position in the industry, and supporting sustainable growth.

 

We maintain an active focus on digital marketing initiatives and business development plans with existing customers. In an effort to optimize our budget, we reduced our participation in tradeshows and redirected resources towards more effective lead generation strategies such as referrals and references. While tradeshows offer valuable networking opportunities, we have found that for the short-term TOMI SteraMist’s strong reputation generates sufficient interest through other channels. These alternative approaches have proven to be more cost-effective and efficient in driving new business and expanding our customer base.

 

We recently launched a targeted campaign aimed at domestic manufacturers of cleanroom construction and general building companies that may require decontamination services as part of their project bids. This outreach extends to both existing partners and new prospects involved in modular cleanrooms, construction design firms, mobile healthcare pods, and related sectors. The campaign has already gained traction, resulting in numerous sales presentations. While many of these opportunities are geared toward long-term engagements, our expanded product offerings and scalable solutions—designed to meet varying industry needs—position us for sustained sales growth in the coming year and beyond.

 

We are steadily increasing our presence in the food safety marketplace primarily from tradeshows we attended in the past. As stated, we must demonstrate that we are a viable solution for this industry, and we are currently conducting numerous feasibility studies with both small and large companies. We have entered the coffee industry with Mayorga Coffee and Organea Terra SRL, the desserts and ice cream industry with Lakeview Farms and Crank and Boom, egg white food manufacturing, pet food production and packaging, and a few agribusinesses have joined in adding iHP SteraMist to their sanitization standard operating procedures.

 

To further highlight the effectiveness of SteraMist iHP technology in the food industry, TOMI announced several collaborative efforts with prominent organizations on new studies exploring expanded applications and benefits of SteraMist iHP. These partnerships have also opened doors to additional opportunities through introductions to their suppliers. One of these collaborations involves a leading producer of health, hygiene, and nutrition products, where we are developing a specialized application for spraying conveyor belts to streamline the decontamination process for packaged goods, targeting pathogens such as Salmonella and Listeria. This initiative represents a significant addition to our client portfolio, aligning with market trends driven by growing health awareness and increasing demand for sustainable, premium products. Additionally, TOMI will soon begin a project with a major conglomerate focused on the decontamination of heart monitoring devices to add to our focus on healthcare initiatives.

 

We would also like to emphasize that we are fully aware of the numerous challenges currently impacting the food market. In response, we have proactively engaged with key industry players to offer our solutions and support.

 

 
33

Table of Contents

 

Key international sales highlights from the third quarter include our expansion into the Indian market, a highly competitive arena within the decontamination sector and a critical focus of TOMI’s global growth strategy. We secured approximately $150,000 in initial purchases, demonstrating our ability to successfully penetrate this challenging market. Establishing a foothold in India underscores the unrivaled effectiveness of SteraMist iHP technology and reinforces our competitive positioning.

 

Additionally, we achieved significant progress in Q3 with one of our platinum customers expanding their use of SteraMist iHP to a facility in South Africa. This marks their fourth location utilizing SteraMist technology and services, following successful implementations in Chile, Portugal, and Brazil.

 

On April 3, 2024, we announced the company has received the Gold Safety Award from Highwire. The award is presented to TOMI in recognition of the Company achieving a score of between 85-94 on the Highwire Safety Assessment. Highwire’s Safety Assessment reviews a company’s historic and current safety performance. The program provides a thorough, objective, and consistent evaluation of company performance so clients and contractors can identify, monitor, and mitigate risks more effectively. The results provide a strong indicator of how a contractor values safety and serve as a reliable predictor of future performance.

 

In evaluating sales related performance, management analyzes our revenue recognized for GAAP purposes which is presented in our quarterly and annual statement of operations as well as our sales orders we receive from customers during those same accounting periods. We define a “sales order” as a document we generate for our internal use in processing a customer order. Our sales orders essentially translate the format of the customer purchase orders we receive from our customers into the format used by us. We also evaluate our “customer sales backlog” which is defined as pending sales orders where revenue has not yet been recognized. Management believes analyzing the sales order and backlog metrics are useful in measuring our overall sales and business development performance as it gauges the overall volume of sales and business development activities.

 

Product Development

 

Our recent products developed and launched are as follows:

 

SteraMist Engineering continues to make strides collaborating with key manufactures of cleanroom technology and equipment developing a turnkey seamless decontamination integration to chambers, cabinets, passthroughs, isolators, cage washers, heat sterilizers, hot cells and more. TOMI begins this endeavor with a project management, turnkey modular solution, and process design consulting firm that we have partnered with in one of our previous CES projects.

 

In collaboration with certain partners, TOMI proudly introduced the SteraMist Integration System (SIS) product line tailored for enclosure decontamination. The inaugural offering, the Stand-Alone model, previously recognized as the Select Plus, has swiftly gained traction in the market, particularly catering to the Biosafety Cabinet (BSC) segment. This innovative solution offers customers seamless setup and versatility, making it an ideal choice for spaces necessitating a single-applicator decontamination fog.

 

We are actively engaged in discussions with numerous manufacturers to ensure the seamless integration of our SIS Manufacturer line. Our efforts are focused on finding the ideal end user in collaboration with our partners to facilitate the development of a comprehensive package. Once finalized, this standardized solution will significantly expand our reach within the Life Sciences sector.

 

 
34

Table of Contents

 

The SteraMist Hybrid, an integral component of the SteraMist Environment System, SteraMist Hybrid is designed with capabilities to communicate with a facility. The system is strategically positioned in a centralized location of the facility through a docking station and features our newly designed permanently mounted stainless steel applicators.

 

TOMI successfully installed the first official SteraMist Hybrid at Xenith Pharmaceutical F/KA Indigo Pharmaceutical, Inc.’s existing research facility, which selected the SteraMist Hybrid because it met the client’s strict delivery timeline while adhering to the facility’s budget constraints. We remain in specification discussions with Xenith for a Custom Engineered System for a future site dedicated to injectables.

 

Building upon our successful partnership with Indigo we continued to cultivate strong relationships within our existing network. In July, the same consultant who introduced Indigo brought BeSpoke Pharmaceuticals, a compounding pharmacy, to our attention. We successfully delivered a Hybrid system to BeSpoke, with installation imminent. Like Indigo, BeSpoke has committed to a marketing initiative to promote our Hybrid product line. These strategic partnerships underscore the effectiveness of our focused approach to business development. By prioritizing existing relationships and leveraging referrals, we are generating tangible results and accelerating revenue growth compared to traditional lead generation methods such as tradeshows.

 

This partnership has proven highly effective, with these facilities now purchasing mobile units and pallets of solution through the Nevada-based consultant. His expertise has been instrumental in driving broader adoption of SteraMist iHP technology across multiple sites and uses of SteraMist iHP.

 

We have seen positive reception of its SteraMist Transport unit, an all-in-one dual voltage fogging product designed to treat a wide variety of vehicle sizes with an application time of only 20 minutes per 1,000 cubic feet. The initial batch of this innovative product is currently in a soft launch phase and was sold for live practical assessment with an existing international customer and domestic distributor.

 

TOMI launched its fourth generation SteraMist Environment System. The 24-volt model allows for universal outlet usage and convert even more of the hydrogen peroxide BIT Solution to hydroxyl radicals thus lowering H2O2 PPM levels allowing for faster turnaround time. In addition, the unit has eight (8) outputs where four (4) are dedicated to our regular process of Constant or Pulse Injection, Dwell, and Aeration along with a light beacon status bar and four (4) are programmable to meet the customer needs for any external equipment they may desire to work with the system. This system is currently on the market and remains to be one of our most popular quoted product lines, has been implemented by customers, and is receiving praise for its further developments.

 

Our SteraMist® BIT solution product line is currently made up of a 32-ounce bottle for the SteraPak, a ten (10) liter, five (5) gallon, 55-gallon drum for our custom built-ins and our traditional one (1) gallon bottle. This brings the BIT Solution product line to a total of five (5) options provided to our customers, which will benefit our razor/razor-blade business model, where our SteraMist delivery systems represent the razor, and our proprietary BIT Solution represents the razor blade.

 

 
35

Table of Contents

 

We expect these new products and service introductions will positively impact our net sales, cost of sales and operating expenses during this fiscal year.

 

Overview

 

TOMI Environmental Solutions, Inc. (“TOMI,” “we,” “our,” or the “Company”) is a global leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Our flagship product, SteraMist, uses our patented and registered Binary Ionization Technology (“BIT”) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas.

 

Developed under a grant from the United States Defense Advanced Research Projects Agency (“DARPA”), SteraMist generates ionized Hydrogen Peroxide (“iHP”) using cold plasma science. BIT transforms a sole active ingredient hydrogen peroxide solution into iHP through a high voltage atmospheric cold plasma arc, producing submicron to 3-micron hydroxyl radical particles that effectively treat surfaces and environments with the same velocity and characteristics of a gas. Our innovative and novel process ensures eradication of pathogens with a 6-log (99.9999%) and greater kill rate, effectively leaving no harmful by-products lingering in the treated area. SteraMist’s innovative methodology, inspired from atmospheric chemistry, not only guarantees effectiveness but also maintains a commitment to environmental sustainability by ensuring the only by-product from the process is oxygen and humidity, a complete package of benefits unmatched in its industry.

 

We owe our success to the collaborative efforts of Titan Defense and DARPA who uncovered a superior technology that mimics nature’s cleansing mechanism, bringing this natural phenomenon indoors providing a competitive edge that exceeds the capabilities of our competition in the healthcare disinfection, life sciences decontamination, and food safety sanitization markets.

 

We believe that we possess the best technologies in the world in the disinfection and decontamination space. The COVID-19 pandemic along with the needs of the pharmaceutical and vivarium space has provided us with the opportunity and experience to implement a clear strategy to develop and manufacture additional products to add to our portfolio. In addition, we continue to move our BIT technology as a standard in disinfection and decontamination globally. This should lead to increased market share, profitability, and capability strength.

 

Our products are an environmentally friendly solution, and our processes address the concerns of sustainability. Customers are requesting and discussing the positive results of our product and the environmentally friendly results compared to the caustic and environmentally unfriendly results of many other disinfectants.

 

SteraMist has established a successful track record in fighting pandemics and outbreaks and implementing SteraMist for emergency preparedness is vital. The COVID-19 pandemic took the world by surprise, and history has shown that other pandemics and viruses are likely to follow. Using a proven and trusted disinfectant for emergency outbreaks and daily for preventative maintenance, such as SteraMist, can alleviate the threat of infections from spreading and could stop a possible outbreak.

 

 
36

Table of Contents

 

The Science Behind the Technology

 

Introducing a revolutionary approach to disinfection and decontamination, our technology offers a streamlined and effective solution. By harnessing the power of atmospheric chemistry, our process converts 7.8% hydrogen peroxide into a plasma-generated hydroxyl radical, achieving a 6-log and greater kill of pathogens leaving only oxygen and humidity as by-products. It is a simple yet effective solution that sets a new standard for global cleaning disinfection decontamination practices.

 

BIT technology was initially developed in response to weaponized anthrax spore attacks, and detailed testing performed by DARPA demonstrated the success of the technology in neutralizing chemical warfare agents. BIT, a TOMI patented process aerosolizes and activates a low concentration hydrogen peroxide solution, producing a fine aqueous mist (0.3-3 um in diameter) that contains a high concentration of hydroxyl radicals (“.OH”). The .OH damages pathogenic and resistant organisms (such as bacteria, bacteria spores, viruses, mold spores, other fungi, and yeast) via oxidation of proteins, carbohydrates, and lipids and rendering the building blocks of nature’s amino acids, DNA and RNA inactive – leading to complete cellular disruption.

 

The unique alteration of the chemistry occurs only once BIT solution passes through the atmospheric cold plasma arc, which causes the breaking of the double bond of a hydrogen peroxide molecule and results in an .OH hydroxyl radical known as iHP. This patented process allows these hydroxyl radicals to exist in high concentrations without rapidly recombining and losing reactivity, while seeking all surfaces within the proximity of the resulting mist or fog.

 

TOMI has and continues to adapt this innovative technology into an everyday solution for use by multiple industries. Under the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), we are mandated to register our disinfectants with the Environmental Protection Agency (“EPA”) and specific state regulatory bodies. SteraMist BIT was EPA-registered (#90150-2) in June 2015 as a hospital-healthcare and broad-spectrum surface disinfectant for misting/fogging applications. We achieved a cutting-edge claim on the EPA label and was coined as the first equipment + solution combination hospital-healthcare disinfectant on the market and maintain the claim as the only EPA Registered Solution + Equipment combination that provides the unique technology of hydrogen peroxide ionization.

 

Today our EPA registered BIT solution is manufactured at an EPA-registered solution blender and our product performance is supported by Good Laboratory Practice (“GLP”) efficacy data which includes mold control and air/surface remediation with claims to combat Staphylococcus, Pseudomonas, MRSA, Salmonella, H1N1, Clostridium difficile spores, and Norovirus. In March 2020, our EPA label was updated to include claims against Emerging Viral Pathogens, meeting criteria for both Enveloped and Large Non-enveloped viruses. In 2021, SteraMist BIT 0.35% hydrogen peroxide received its EPA registration (#90150-3), and on June 2, 2022, SteraMist was added to its seventh EPA’s List, List Q for combating rare or novel viruses like Monkeypox virus and SARS-CoV-2 variants causing COVID-19.

 

TOMI continuous to build its portfolio of feasibility studies with renowned and trusted partners. In 2023, the U.S. Department of Defense’s BSAT Biorisk Program Office and the Department of Homeland Security’s Science and Technology Directorate’s Plum Island Animal Disease Center published a report demonstrating that iHP is an effective tool for decontamination of biological toxoids and dangerous pathogens that may disrupt our world. We maintain registrations in all 50 states, Washington D.C., Canada, and approximately 40 other countries. These endorsements signify our commitment to safeguarding our world against any potential threats.

 

 
37

Table of Contents

 

Industries & Market Segments

 

SteraMist products are designed to address a wide spectrum of industries using iHP. Our operations consist of four main divisions based on our current target industries: Life Sciences, Hospital-HealthCare, Food Safety, and Commercial. Launched in sequential order as listed to either strategically address the needs and/or ensure compliance with the specific regulations governing each industry segment.

 

Life Sciences

 

SteraMist iHP is designed to be tailored to provide a complete solution to address the regulatory inspections of disinfecting/decontaminating and Installation Qualification (IQ)-Operational Qualification (OQ)–Performance Qualification (PQ) validation processes within the life sciences industry.

 

The life sciences sector demands rigorous decontamination procedures to ensure the integrity and safety of pharmaceutical products, medical devices, and research environments. With the evolving landscape of the pharmaceutical market, there is an increasing demand for fully automated decontamination products that offer quick turnaround times to minimize downtime and expedite production cycles.

 

The life sciences industry was among the first to embrace the Company’s innovative decontamination solutions, recognizing the limitations of traditional methods and effects on progress. Our current portfolio of life science customers, including Fortune 100 companies, has been able to overcome the constraints imposed by outdated practices, paving the way for enhanced efficiency, safety, and productivity in their operations. Their early adoption of our SteraMist iHP lays a solid foundation for our future expansion. By demonstrating the effectiveness and value in a highly regulated and demanding sector, we establish credibility and trust that can facilitate broader adoption across other facilities, companies, and even industries.

 

The insights gained from working closely with life sciences companies also inform our product development and service offerings, enabling us to better meet the evolving needs of markets. In today’s pharmaceutical market, characterized by rapid innovation, stringent regulatory requirements, and global competition-efficiency and speed are paramount. Pharmaceutical companies, including Contract Development and Manufacturing Organizations (“CDMO”), are under pressure to streamline their operations while maintaining high standards of quality and compliance.

 

According to industry statistics, the global pharmaceutical market is projected to grow steadily, with emerging markets playing an increasingly significant role in driving growth. As their operations expand globally, there is a growing need for decontamination solutions that can deliver consistent fast results across the dynamic and ever-changing landscape of manufacturing and production facilities and research laboratories.

 

By offering fully automated products and services tailored to the unique requirements of pharmaceutical manufacturers and CDMOs, TOMI aims to support their efforts in maintaining the highest standards of quality, safety, and efficiency on a global scale.

 

Hospital-Healthcare

 

TOMI focuses on the Hospital-Healthcare Market by providing high quality of safety to patients and personnel by disinfecting operating rooms, pharmacies, ambulances, and emergency environments throughout a healthcare facility.

 

 
38

Table of Contents

 

Healthcare facilities worldwide should prioritize disinfection to mitigate the risk of healthcare-associated infections (“HAI”), enhance patient safety, and maintain a sterile environment conducive to healing. According to the World Health Organization, HAIs affect millions of patients globally each year, leading to prolonged hospital stays, increased healthcare costs, and deaths.

 

In 2024, it is estimated that approximately 7-10% of patients admitted to healthcare facilities worldwide will acquire at least one HAI during their stay. This translates to millions of cases annually, with significant economic burdens and human costs. Furthermore, the emergence of antimicrobial-resistant pathogens poses a growing threat, exacerbating the challenge of infection control in healthcare settings.

 

Effective disinfection measures, including the use of advanced technologies like SteraMist, are essential for reducing the incidence of HAIs and safeguarding patient health. By implementing rigorous disinfection protocols, healthcare facilities can significantly reduce the risk of infections, improve patient outcomes, and promote public health, but may also reduce healthcare costs and enhances the overall quality of care provided.

 

TOMI will intensify its efforts to penetrate the healthcare market by forging strategic partnerships and advocating for the adoption of advanced disinfection technologies. By collaborating with key stakeholders, including healthcare providers, facility managers, group purchasing organizations (“GPO”) like Vizient and regulatory bodies, we can promote the integration of SteraMist as a complementary solution to manual cleaning practices. Emphasizing the efficiency, efficacy, and cost-effectiveness of SteraMist in eliminating pathogens and reducing the risk of healthcare-associated infections will be essential in gaining traction in the market. Additionally, investing in targeted marketing campaigns and educational initiatives to raise awareness about the benefits of automated disinfection processes can help overcome resistance to change and accelerate market penetration.

 

Food Safety

 

Every day there are news articles around the world pertaining to the contamination of food supply. Unsafe food containing harmful bacteria, viruses, parasites, or chemical substances causes more than 200 diseases. It also creates a vicious cycle of disease and malnutrition, particularly affecting infants, young children, elderly and the sick. With the global population explosion, severe worldwide avian flu pandemics resulting in the unnecessary culling of bird flocks, unusually high number of accidents resulting in the destruction of dozens of storages, packing and processing food plants, in the U.S. alone, we anticipate an increase in the demand for a mechanical way to sanitize the food supply. TOMI, in cooperation with the USDA, demonstrated that our technology offers a consistent, quick, and effective solution.

 

Sanitation procedures must be implemented regularly and effectively to maintain cleanliness and prevent cross-contamination throughout the food processing chain. This includes proper cleaning and sanitizing of food preparation areas, storage facilities, transportation vehicles, and equipment used in food production. New challenges to food safety will continue to emerge, largely due to changes in the environment, new and emergent bacteria, toxins, and antimicrobial resistance. Food Safety presents an opportunity for significant growth for TOMI with continued product research and compliance testing.

 

 
39

Table of Contents

 

Compliance with food safety regulations is essential for food businesses to protect public health, uphold consumer trust, and meet legal requirements. Regulatory agencies such as the United States Food and Drug Administration (“FDA”) and the European Food Safety Authority, as well as the Canadian Safe Food for Canadians Act and Safe Food, establish and enforce sanitation standards to ensure the safety and quality of the food supply. Failure to comply with sanitation regulations can result in fines, product recalls, legal actions, and damage to the reputation of food businesses. Therefore, adherence to sanitation practices is paramount in the food industry to mitigate risks and maintain food safety standards.

 

We have made significant strides in boosting brand awareness within the food safety industry through targeted promotion and marketing initiatives. Leveraging a similar strategy to what proved successful in the Life Sciences sector, we focused on building a customer base through referrals and feasibility studies, gradually expanding our reach. By fostering relationships with key supporters of our technology and remaining patient in our approach, we have finally laid a foundation and expect to continue to expand and grow our presence in this critical market segment.

 

Commercial

 

In line with adopting a proactive approach through our TOMI Service Network, it’s imperative for the entire commercial world to follow suit. Proactive disinfection practices not only ensure the health and safety of employees, customers, and visitors but also safeguard business continuity and reputation. Our Commercial division includes, but is not limited to, use sites such as aviation, airports, police and fire, prisons, manufacturing companies, automobile, gymnasiums, cruise ships, shipping ports, preschool education, primary and secondary schools, colleges including dormitories, all modes of public and private transportation, regulatory consulting agencies, retail, housing and recreation, and of course emergency preparedness for counties and cities use of SteraMist throughout such communities.

 

SteraMist disinfection helps prevent the spread of harmful pathogens, including bacteria and viruses, reducing the risk of illnesses and infections among individuals. This is particularly crucial in shared spaces such as offices, retail stores, and restaurants where people gather regularly. A healthy and safe work environment promotes employee well-being and productivity. By reducing absenteeism due to illness and creating a comfortable workspace, disinfection measures contribute to a more efficient and effective workforce. For businesses in the service industry, such as hotels, restaurants, and retail stores, providing a clean and hygienic environment is essential for delivering a positive customer experience. Cleanliness influences customer perceptions and can impact loyalty and repeat business. Disinfection helps mitigate the risk of liability claims associated with poor health and safety practices. Implementing proactive disinfection measures can minimize the potential for legal and financial repercussions resulting from health-related incidents.

 

TOMI, in conjunction with its partners, collaborators, and industry associations, is proactively educating the community on the importance of preventive disinfection through verbal explanation and visual demonstrations of the impact of maintaining a clean environment. We engage in targeted social media campaigns, offer training programs and workshops on best practices, and share case studies of real-life examples highlighting the long-term benefits in promoting health and safety for a successful business.

 

By further implementing these strategies and our reach, we can effectively convey the importance of proactive disinfection and inspire action among businesses and individuals to prioritize cleanliness and hygiene in commercial settings.

 

 
40

Table of Contents

 

The Company is committed to further expanding its marketing, advertising, and educational campaigns aimed at its customer base and driving adoption of our SteraMist iHP product line across all our industries: Life Sciences, Hospital-Healthcare, TOMI Service Network, Food Safety, and Commercial. We will continue to innovate and develop tailored products to meet the specific needs of each, ensuring seamless implementation and optimal performance. Our dedicated team of technicians and representatives will continue to provide comprehensive training, maintenance, and servicing of capital equipment worldwide, supporting customers in maximizing the benefits of our patented technology. Additionally, TOMI will continue to offer protocol development and implementation services for SteraMist iHP, recognizing its critical role in various settings, particularly in pandemic preparedness scenarios.

 

SteraMist Pro Certified (“SPC”) - New Program Offering

 

The TOMI Service Network or TSN, an expansive network consisting of professionals who are exclusively licensed and trained to use the SteraMist products. TOMI trained and serviced a wide array of professional remediation companies in the use of SteraMist. The TSN addressed many cleaning protocols that changed permanently due to the COVID-19 pandemic, a network that played a significant role in facilitating and maintaining these protocols. COVID-19 highlighted the limitations of reactive approaches to cleanliness and hygiene. Recognizing this, TOMI is now championing a proactive approach to disinfection. While the pandemic may have initially spurred reactive measures, we are advocating for a shift towards proactive, ongoing disinfection protocols.

 

Through consistent and persistent efforts, we are slowly but steadily changing minds across all industries that individuals interact with in their daily lives. By emphasizing the importance of maintaining clean and safe environments as a preemptive measure providing long-term benefits of proactive disinfection in ensuring the health and well-being of their employees, customers, and communities, rather than merely reacting to immediate threats, we are promoting a culture of preventive healthcare. To do this more widely, we needed to offer something more than the SPC to the world.

 

The SteraMist Pro Certified (SPC) program signifies a significant step towards industry excellence. Our aim is to establish a standard that reflects a commitment to continuous improvement, adherence to evolving disinfection and biohazard response norms, and dedication to setting benchmarks in the field.

 

Central to our mission is ensuring that the SPC program resonates with consumers by placing their needs at the forefront, portraying the certification as user-centric rather than SteraMist-centric. This approach is crucial in garnering recognition and legitimacy for the certification.

 

In optimizing our communication, offerings, and requirements, we are prioritizing the categorization of Certification participants: Individuals, Sole Proprietors/Small Businesses, Franchises, and Internal/Departments. This classification will enable us to tailor our approach and support to meet the specific needs and challenges faced by each group.

 

 
41

Table of Contents

 

As we move forward, the SteraMist Pro Certified (SPC) program will encompass a comprehensive set of criteria to ensure industry-leading standards. This includes:

 

 

1.

SteraMist equipment ownership: Demonstrating a commitment to utilizing SteraMist technology for effective disinfection.

 

 

 

 

2.

Public health commitment: Upholding a dedication to safeguarding public health through rigorous disinfection practices.

 

 

 

 

3.

Training excellence: Ensuring thorough and ongoing training for personnel involved in disinfection procedures.

 

 

 

 

4.

Employee awareness and training: Fostering a culture of awareness and competence among staff regarding disinfection protocols.

 

 

 

 

5.

Equipment maintenance assurance: Guaranteeing the proper maintenance and upkeep of SteraMist equipment to optimize performance.

 

 

 

 

6.

Internal self-audit program: Implementing regular self-assessment processes to monitor and improve disinfection practices.

 

 

 

 

7.

Customer feedback innovation: Embracing customer feedback to drive innovation and enhance service delivery.

 

 

 

 

8.

Continuous improvement documentation: Documenting efforts to continuously enhance disinfection practices and procedures.

 

 

 

 

9.

Environmental sustainability commitment: Incorporating environmentally sustainable practices into disinfection operations.

 

 

 

 

10.

Emergency response plan with risk assessment: Developing comprehensive plans and risk assessments to effectively respond to emergencies.

 

The SPC program seeks to ensure certified entities are equipped to deliver disinfection decontamination while prioritizing public health, safety, and environmental sustainability.

 

As a result, we will no longer maintain the TOMI Service Network (TSN) in its current form. Instead, we launched a proactive program now available to all our customers—including those in Life Sciences, Healthcare, Food Safety, and Commercial sectors. This on-demand program reflects our proactive approach, leveraging the expertise of all partners and key relationships to strengthen our brand and global presence. Through these valuable relationships we have built with industry experts, we continue to advance contamination control and validation practices.

 

With SteraMist iHP, we now have a game-changing technology across four key industries, capable of addressing everything from routine cleaning to complex cleanroom decontamination, patient healthcare environments, biohazard management, and border control along with an educational platform. Our domestic and international service provider partnerships are essential in driving this mission forward and expanding our impact worldwide.

 

 
42

Table of Contents

 

Business Highlights and Recent Events

 

Revenues

 

Total revenue for the nine months ended September 30, 2024, was $6,670,000, a 14.5% increase or $843,000 compared to $5,827,000 for the nine months ended September 30, 2023. This growth was driven by higher sales of SteraMist products and iHP Service Revenue.

 

SteraMist product-based revenue, which is primarily comprised of our mobile and CES equipment, was up 85% in the third quarter of the current year, when compared to the same prior year period.

 

Our third-quarter international revenue grew by 230%, driven by new customers in Canada, South Africa and the India, compared to the same period in 2023.

 

2024 Events:

 

On April 15, 2024, we announced our attendance at Interphex 2024 showcasing our new innovations. Interphex 2024 provides an opportunity for a wide range of biotechnology industry leaders to discover SteraMist’s groundbreaking iHP technology which was held in New York City on April 16-18, 2024.

 

One June 6, 2024, we announced comprehensive cost reduction initiatives to align the Company’s cost structure with targeted profitability objectives. The Company’s operational cash savings initiatives include a modification of compensation arrangement for our executive officers, pursuant to which executives will reduce their compensation by 30% of their current cash compensation for the remainder of 2024, and an optimization of our consulting arrangement, under which we terminated select external consulting agreements, with remaining consultants agreeing to reduce their consultant fees.

 

On June 13, 2024, we announced two recent sales in the Life Sciences sector, underscoring the Company’s successful strategic expansion in the sector and growth potential. The first purchase agreement, signed with one of the largest private pharmaceutical companies in the world, includes the acquisition of a SteraMist Environment System and TOMI validation services for the client’s vivarium facility in Mexico. The second purchase agreement arises from the Company’s collaboration with a trusted partner with decades of experience in big pharma. This partnership facilitated the sale of the first Hybrid System to Indigo Pharmaceutical, Inc. as announced in September 2023. Continuing this momentum, the partner has now successfully sold another SteraMist Hybrid System to BeSpoke Pharmaceuticals, a Nevada-based manufacturer targeting 503B products.

 

On July 24, 2024, we announced that EMAQ Group, Inc. purchased twenty (20) SteraMist Environment Systems, generating $1,180,280 in revenue which was recognized in the second quarter of 2024. This strategic partnership aims to enhance the market penetration of SteraMist iHP decontamination solutions within the pharmaceutical industry and is expected to grant SteraMist iHP technology the significant traction it deserves, delivering decontamination solutions that meet the stringent demands of the pharmaceutical sector.

 

On August 22, 2024, we announced the expansion of its partnership with a global leader in laboratory testing and diagnostics services with multiple mobile equipment purchases and a Custom Engineered System (CES) to support the expansion of their Wisconsin facility.

 

On September 6, 2024, we announced that Elissa J. Shane, Chief Operating Officer, and Joe Rzepka, Chief Financial Officer, will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

 

 
43

Table of Contents

 

Intellectual Property

 

Our success depends in part upon our ability to obtain and maintain proprietary protection for our products and technologies. We protect our technology and products by, among other means, obtaining United States and foreign patents. In addition, the process of obtaining and protecting patents can be long and expensive. We also rely upon trade secrets, technical know-how, and continuing technological innovation to develop and maintain our competitive position.

 

As part of our intellectual property protection strategy, we have registered our BIT™ solution with the EPA, all 50 states in the United States, and multiple countries worldwide. We have received or are in the process of receiving Conformité Européene (“CE”) marks in the European Economic Area (“EEA”) and are approved by Underwriters Laboratory (“UL”).

 

Our portfolio includes more than 25 Utility or Design Patents worldwide which expire at various dates through the year 2038 for both method and system claims on SteraMist® BIT™, as well as design of devices. We continue to pursue further claims to additional capabilities in on-going United States and worldwide patent applications; we have recently obtained new patents in Mexico and Japan. We have obtained four related United States utility patents, giving us protection of our technology until the year 2038; we are currently pursuing allowance for a fifth US patent for our backpack decontamination units and mobile carts. We have obtained utility patents for our technologies in diverse countries such as Brazil, Japan, Korea, Israel, Australia, Taiwan, Canada, Mexico, Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Portugal, Romania, Slovenia, and Sweden, Singapore, New Zealand, and in the UK, and continue to pursue protections all over the world.

 

We have submitted utility patent applications in multiple jurisdictions and countries, including Europe, China, Brazil, Korea and Australia for further additional applications of SteraMist BIT, and a related application has already been determined novel and inventive in Taiwan, Japan, Israel, New Zealand, Australia and Singapore. We have recently filed new patent pending applications on novel uses and enhancements of our technology in the United States. We have been awarded a design patent on our surface-mounted applicator device in the United States, China, Japan, Taiwan, and Korea. We have filed and have been granted or have pending acceptance on 32 separate design patents for our: Decontamination Chamber(s), Decontamination Applicator, Decontamination Cart, Applicator, and Surface Mounted Applicator 90-Degree Device. These patents are published around the world, including but not limited to the United States, China, Hong Kong, Europe, United Kingdom, Singapore, Taiwan, Vietnam, Canada, South Korea, and Japan. We are also pursuing IP protection for further applications of our SteraMist BIT in diverse fields in multiple jurisdictions, such as food decontamination and, in installed systems for the application of iHP for the protection of buildings post outbreak or after a biological attack. With worldwide attention on the etiology of SARs CoV2 coming from a lab leak, attention on the prevention and control of a leak or mishap should be on the mind of all the biological labs managers around the world. The fact that iHP and our BIT platform can be incorporated in new or existing buildings to create an “immune building” should assist in further lab applications of SteraMist in the biosecurity industry in the future. Our current patents with claims to systems already serve to provide protection for our technology in this area and our on-going pending applications will further enhance the scope of our intellectual property. Recently, we have filed new patent applications, both in the United States and internationally, which are directed to improved applicator designs, and designs for applications in cell biology; these new designs have been found novel during review in the World Intellectual Property Organization international application process. Initial findings for our filed improved applicator designs in cell biology may be followed by accelerated applications in many countries.

 

 
44

Table of Contents

 

Our products are sold around the world under various brand names and trademarks. We consider our brand names and trademarks to be valuable in the marketing of our products. As of today, we have over two hundred trademarks or trademark applications, (word and/or logo) registered or pending across the globe. TOMI registers marks in eight classes of specification of goods and services: Class 1 for Chemicals for Treating Hazardous Waste, Class 5 for Disinfectants, All-Purpose for Hard Surfaces and for Treating Mold, Class 7 for Handheld Power Operated Spraying Machines, Class 11 for Sterilizers for Medical Use and Air Purification, Class 35 for Business Consultation and Management Services, Class 37 for General Disinfecting Services, Class 40 for Chemical Decontamination and Manufacturing Services, and Class 41 for Providing Education Training and information related to biological and bacterial decontamination services. Recently, we have expanded our trademark protection into India.

 

Financial Operations Overview

 

Our financial position as of September 30, 2024 and December 31, 2023, respectively, was as follows:

 

 

 

September 30, 2024

(Unaudited)

 

 

December 31,

2023

 

Total shareholders’ equity

 

$7,355,000

 

 

$8,359,000

 

Cash and cash equivalents

 

$809,000

 

 

$2,339,000

 

Accounts receivable – Current, net

 

$3,146,000

 

 

$2,430,000

 

Inventories

 

$4,580,000

 

 

$4,627,000

 

Prepaid expenses

 

$346,000

 

 

$371,000

 

Vendor Deposits

 

$97,000

 

 

$29,000

 

Other Receivables

 

$164,000

 

 

$164,000

 

Accounts receivable – Long Term, net

 

$206,000

 

 

$206,000

 

Current liabilities – Excluding Deferred Revenue

 

$2,215,000

 

 

$2,058,000

 

Long-term liabilities – Convertible Notes

 

$2,345,000

 

 

$2,298,000

 

Long-term liabilities – Other

 

$547,000

 

 

$643,000

 

Working Capital

 

$6,928,000

 

 

$7,903,000

 

 

During the nine months ended September 30, 2024, our debt and liquidity positions were affected by the following:

 

 

·

Net cash used in operations of approximately $1,453,000.

 

 
45

Table of Contents

 

Results of Operations for the Three and Nine Months Ended September 30, 2024 Compared to the Three and Nine Months Ended September 30, 2023:

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

Revenue, Net

 

$2,542,000

 

 

$1,470,000

 

 

$1,072,000

 

 

$6,670,000

 

 

$5,827,000

 

 

$843,000

 

Gross Profit

 

 

1,561,000

 

 

 

809,000

 

 

 

752,000

 

 

 

4,086,000

 

 

 

3,450,000

 

 

 

636,000

 

Total Operating Expenses (1)

 

 

1,412,000

 

 

 

1,710,000

 

 

 

(298,000)

 

 

5,042,000

 

 

 

5,629,000

 

 

 

(587,000)

Income (Loss) from Operations

 

 

149,000

 

 

 

(901,000)

 

 

1,050,000

 

 

 

(956,000)

 

 

(2,179,000)

 

 

1,223,000

 

Total Other Income (Expense)

 

 

(90,000)

 

 

-

 

 

 

(90,000)

 

 

(265,000)

 

 

1,000

 

 

 

(266,000)

Provision for (benefit from) Income Taxes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net Income (Loss)

 

$59,000

 

 

$(901,000)

 

 

960,000

 

 

$(1,221,000)

 

$(2,178,000)

 

 

957,000

 

Basic Net Income (Loss) per share

 

$0.00

 

 

$(0.05)

 

$0.05

 

 

$(0.06)

 

$(0.11)

 

$0.05

 

Diluted Net Income (Loss) per share

 

$0.00

 

 

$(0.05)

 

$0.05

 

 

$(0.06)

 

$(0.11)

 

$0.05

 

 

Revenue

 

Total revenue for the three months ended September 30, 2024 and 2023, was $2,542,000 and $1,470,000, respectively, representing an increase of $1,072,000 or 73% compared to the same prior year period. Product based revenues for the nine months ended September 30, 2024 and 2023, were $5,247,000 and $4,501,000, representing an increase of $746,000 or 17% when compared to the same prior year period.  The higher revenue was attributable to increased demand for our mobile units and higher iHP service revenue.

 

As customers mature through the product and adoption cycle and our sales pipeline converts to revenue, we expect to generate more predictable sales quarter over quarter.

 

Product and Service Revenue

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

SteraMist Product

 

$1,766,000

 

 

 

953,000

 

 

$813,000

 

 

$5,247,000

 

 

$4,501,000

 

 

$746,000

 

Service and Training

 

 

776,000

 

 

 

517,000

 

 

 

259,000

 

 

 

1,423,000

 

 

 

1,326,000

 

 

 

97,000

 

Total

 

$2,542,000

 

 

$1,470,000

 

 

$1,072,000

 

 

$6,670,000

 

 

$5,827,000

 

 

$843,000

 

 

SteraMist Product-based revenues for the three months ended September 30, 2024 and 2023, were $1,776,000 and $953,000, representing an increase of $813,000 or 85% when compared to the same prior year period. The higher revenue was attributable to increased demand for our mobile units and higher iHP service revenue.  For the nine months ended September 30, 2024 and 2023, our total revenue was $6,670,000 and $5,827,000, respectively, representing an increase of $843,000, or 14% compared to the same prior year period.

 

Our service-based revenue for the three months ended September 30, 2024 and 2023, was $776,000 and $517,000, respectively, representing an increase of $259,000 or 50%. For the nine months ended September 30, 2024 and 2023, our service-based revenue was $1,423,000 and $1,326,000, representing an increase of $97,000 or 7% when compared to the same prior period in 2023. The increase in service revenue was due to timing of emergency service work that occurred in the same prior period.

 

 
46

Table of Contents

 

Revenue by Geographic Region

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

United States

 

$1,886,000

 

 

$1,271,000

 

 

$615,000

 

 

$5,169,000

 

 

$5,001,000

 

 

$168,000

 

International

 

 

656,000

 

 

 

199,000

 

 

 

457,000

 

 

 

1,501,000

 

 

 

826,000

 

 

 

675,000

 

Total

 

$2,542,000

 

 

$1,470,000

 

 

$1,072,000

 

 

$6,670,000

 

 

$5,827,000

 

 

$843,000

 

 

Our domestic revenue for the three months ended September 30, 2024 and 2023 was $1,886,000 and $1,271,000, respectively, an increase of $615,000 or 48%, when compared to the same prior year period. For the nine months ended September 30, 2024 and 2023, our domestic revenue was $5,169,000 and $5,001,000, representing an increase of $168,000 or 3% when compared to the same prior period in 2023. Our domestic product-based revenue increased due to higher domestic demand for our equipment and iHP services.

 

Internationally, our revenue for the three months ended September 30, 2024 and 2023, was approximately $656,000 and $199,000, respectively, representing an increase of $457,000 or 230% when compared to the same prior year period. For the nine months ended September 30, 2024 and 2023, our international revenue was $1,501,000 and $826,000, representing an increase of $675,000 or 82% when compared to the same prior period in 2023. The higher revenue was attributable to increased demand for our mobile units.

 

Cost of Sales

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

2024

 

 

2023

 

 

$

 

Cost of Sales

 

$981,000

 

 

$661,000

 

 

$320,000

 

 

$2,583,000

 

 

$2,376,000

 

 

$207,000

 

 

Cost of sales was $981,000 and $661,000 for the three months ended September 30, 2024 and 2023, respectively, an increase of $320,000 or 48%, compared to the prior year. The increase in cost of sales was primarily due to higher sales. Our gross profit as a percentage of sales for the three months ended September 30, 2024 was 61% compared to 55% in the same prior period, respectively. The higher gross profit is attributable to the product mix in sales.

 

Cost of sales was $2,583,000 and $2,376,000 for the nine months ended September 30, 2024 and 2023, respectively, an increase of $207,000, or 9%, compared to the prior year. The increase in cost of sales was primarily due to the higher sales.

 

 
47

Table of Contents

 

Professional Fees

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

Professional Fees

 

$105,000

 

 

$208,000

 

 

$(103,000)

 

$387,000

 

 

$457,000

 

 

$(70,000)

 

Professional fees are comprised mainly of legal, accounting, and financial consulting fees.

 

Professional fees were $105,000 and $208,000 for the three months ended September 30, 2024 and 2023, respectively, a decrease of approximately $103,000 or 50%, in the current year period. The decrease in professional fees was due to lower legal fees incurred in the current year period due to costs incurred in connection with our intellectual property and the related timing of when those services were rendered.

 

Professional fees were $387,000 and $457,000 for the nine months ended September 30, 2024 and 2023, respectively, a decrease of approximately $70,000, or 15%, in the current year period. The decrease in professional fees was primarily due to lower legal fees we incurred in connection with distributor and OEM agreements.

 

Depreciation and Amortization

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

Depreciation and Amortization

 

$70,000

 

 

$94,000

 

 

$(24,000)

 

$224,000

 

 

$273,000

 

 

$(49,000)

 

Depreciation and amortization were approximately $70,000 and $94,000 for the three months ended September 30, 2024 and 2023, respectively, representing a decrease of $24,000 or 26%.

 

Depreciation and amortization were approximately $224,000 and $273,000 for the nine months ended September 30, 2024 and 2023, respectively, representing a decrease of $49,000, or 18%.

 

The decrease in depreciation expense is due to a lower amount of fixed assets being depreciated in the current year period when compared to the same prior year periods.

 

Selling Expenses

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

Selling Expenses

 

$227,000

 

 

$283,000

 

 

$(56,000)

 

$882,000

 

 

$1,161,000

 

 

$(279,000)

 

 
48

Table of Contents

 

Selling expenses for the three months ended September 30, 2024 were approximately $227,000, as compared to $283,000 for the quarter ended September 30, 2023, representing a decrease of approximately $56,000 or 20%. The decline in selling expenses is due to lower sales commission incurred in the current year period due to less sales generated by third party representatives and lower advertising and tradeshow costs incurred in the current year period.

 

Selling expenses for the nine months ended September 30, 2024 were approximately $882,000, as compared to $1,161,000 for the quarter ended September 30, 2023, representing a decrease of approximately $279,000 or 24%. The decline in selling expenses is due to lower sales commission incurred in the current year period due to less sales generated by third party representatives and lower advertising and tradeshow costs incurred in the current year period.

 

Research and Development

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

Research and Development

 

$56,000

 

 

$76,000

 

 

$(20,000)

 

$186,000

 

 

$221,000

 

 

$(35,000)

 

Research and development expenses for the three months ended September 30, 2024 were approximately $56,000, as compared to $76,000 for the quarter ended September 30, 2023, representing a decrease of approximately $20,000 or 26%. The decline in research and development expenses is due to the timing projects that occurred in the prior period which did not recur in the same current year period.

 

Research and development expenses for the nine months ended September 30, 2024 were approximately $186,000, as compared to $221,000 for the quarter ended September 30, 2023, representing a decrease of approximately $35,000, or 16%. The decline in research and development expenses is due to the timing projects that occurred in the prior period which did not recur in the same current year period.

 

The decline in research and development expenses is due to the timing projects that occurred in the prior period, which did not recur in the same current year period.

 

Consulting Fees

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

2024

 

 

2023

 

 

$

 

Consulting Fees

 

$44,000

 

 

$44,000

 

 

$-

 

 

$181,000

 

 

$189,000

 

 

$(8,000)

 

Consulting fees were $44,000 and $44,000 for the three months ended September 30, 2024 and 2023, respectively, representing no change in the current quarter period.

 

 
49

Table of Contents

 

Consulting fees were $181,000 and $189,000 for the nine months ended September 30, 2024 and 2023, respectively, representing a decrease of $8,000, or 4%, in the current quarter period.  

 

The decrease in consulting fees is due to termination of select external consulting agreements, with remaining consultants agreeing to reduce their consultant fees, as part of our cost-reduction measures implemented June 2024.

 

General and Administrative Expense

 

 

 

For The Three Months Ended

September 30,

 

 

Change

 

 

For The Nine Months Ended

September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

2024

 

 

2023

 

 

$

 

General and Administrative

 

$910,000

 

 

$1,005,000

 

 

$(95,000)

 

$3,181,000

 

 

$3,329,000

 

 

$(148,000)

 

General and administrative expenses include salaries and payroll taxes, rent, insurance expense, utilities, office expense, product registration costs, equity compensation and bad debt expense.

 

General and administrative expenses were $910,000 and $1,005,000 for the three months ended September 30, 2024 and 2023, respectively, a decrease of $95,000 or 9% in the current period. The decrease is attributable to the reduction in executive salaries and reduced overhead related to the closing of a satellite office space.

 

General and administrative expenses were $3,181,000 and $3,329,000 for the nine months ended September 30, 2024 and 2023, respectively, a decrease of $148,000, or 4% in the current period. The decrease in general and administrative expenses was attributable to a decrease in executive compensation and reduced overhead related to the closing a satellite office space.

 

 
50

Table of Contents

 

Other Income and Expense

 

 

 

For The Three Months

Ended September 30,

 

 

Change

 

 

For The Nine Months

Ended September 30,

 

 

Change

 

 

 

2024

 

 

2023

 

 

$

 

 

 2024

 

 

2023

 

 

$

 

Interest Income

 

$3,000

 

 

$-

 

 

$3,000

 

 

$12,000

 

 

$1,000

 

 

$11,000

 

Interest Expense

 

$(94,000)

 

$-

 

 

$(94,000)

 

$(281,000)

 

$-

 

 

$(281,000)

Other Income (Expense)

 

$(91,000)

 

$-

 

 

$(91,000)

 

$(269,000)

 

$1,000

 

 

$(270,000)

 

Interest income was approximately $3,000 and $0 for the three months ended September 30, 2024 and 2023.

 

Interest income was approximately $12,000 and $1,000 for the nine months ended September 30, 2024 and 2023, respectively.

 

Interest expense was $94,000 and $0 for the three months ended September 30, 2024 and 2023, respectively.

 

Interest expense was $281,000 and $0 for the nine months ended September 30, 2024 and 2023, respectively.

 

The interest expense is attributable to the convertible notes.

 

Liquidity and Capital Resources

 

As of September 30, 2024, we had cash and cash equivalents of approximately $809,000 and working capital of $6,928,000. Our principal capital requirements are to fund operations, invest in research and development and capital equipment, and the continued costs of compliance with public company reporting requirements. We have historically funded our operations through funds generated through operations and debt and equity financings. The sale of additional equity securities could result in dilution to our stockholders. The incurrence of indebtedness would result in increased debt service obligations and may include operating and financial covenants that would restrict our operations. We cannot be certain that any financing will be available in the amounts we need or on terms acceptable to us, if at all.

 

For the nine months ended September 30, 2024 and 2023, we incurred losses from operations of ($956,000) and ($2,179,000), respectively. Cash used in operations for the nine months ended September 30, 2024 and 2023 was ($1,453,000) and ($2,362,000), respectively.

 

Our cash and cash equivalents at September 30, 2024 of $809,000 represented an increase of $100,000 when compared to the cash and cash equivalents balance of $709,000, as of June 30, 2024, as we were cash flow positive for the three months ended September 30, 2024.

 

 
51

Table of Contents

 

A breakdown of our statement of cash flows for the nine months ended September 30, 2024 and 2023 is provided below:

 

 

 

For The Nine Months

Ended September 30,

 

 

 

2024

 

 

2023

 

Net Cash Provided (Used) in Operating Activities

 

$(1,453,000)

 

$(2,362,000)

Net Cash Used in Investing Activities

 

$(105,000)

 

$(94,000)

Cash Flow From Financing Activities:

 

$28,000

 

 

$-

 

 

Operating Activities

 

Cash used in operations for the nine months ended September 30, 2024 and 2023 was $1,453,000 and $2,362,000, respectively. The decrease was attributable to a lower current year loss and management’s planned overhead cost reductions.

 

Investing Activities

 

Cash used in investing activities for the nine months ended September 30, 2024 and 2023 was $105,000 and $94,000, respectively. The increase was attributable to higher property and equipment purchased in the current year period.

 

Financing Activities

 

Cash provided by financing activities for nine months ended September 30, 2024 and 2023 was $28,000 and $0, respectively. The increase is attributable to the proceeds from the exercise of stock options.

 

Liquidity

 

Our revenues can fluctuate due to the following factors, among others:

 

 

·

ramp up and expansion of our internal sales force and manufacturer’s representatives;

 

·

length of our sales cycle;

 

·

global and regional response to the outbreak of infectious diseases;

 

·

expansion into new territories and markets; and

 

·

timing of orders from distributors.

 

We could incur operating losses and an increase of costs related to the continuation of product and technology development, sales expense as we continue to grow our sales teams, inventory as we continue to ensure we have products needed and geographic presence, tooling capital expenditures as we ramp up and streamline our production and administrative activities including compliance with the Sarbanes-Oxley Act of 2002 Section 404.

 

Management has taken and will endeavor to continue to take a number of actions in order to improve our results of operations and the related cash flows generated from operations in order to strengthen our financial position, including the following items:

 

 
52

Table of Contents

 

 

·

expanding our label with the EPA to further our product registration internationally;

 

·

continued expansion of our internal sales force and manufacturer representatives in an effort to drive global revenue in all verticals;

 

·

continue research and development and add new products to our “Stera” product line;

 

·

source alternative lower cost suppliers;

 

·

expansion of international distributors; and

 

·

continued growth in all of our verticals.

 

During 2023 and 2024, we experienced increased demand for our CES where we collect deposits upon the execution of the contract. The deposits we receive fund the production for the CES and improve our overall liquidity through the duration of the project. We believe our sales for our CES will continue to grow and improve our financial results from a liquidity perspective as well as improve our operating margins due to the higher recurring solution sales we see for our CES system.

 

We expect that the cash we generate from our core operations will generally be sufficient to cover our future capital expenditures and to pay down our near-term debt obligations.

 

We believe that our existing balance of cash and cash equivalents and amounts expected to be generated by operations will provide us with sufficient financial resources to meet our cash requirements for operations, working capital and capital expenditures over the next twelve months. While we cannot predict our liquidity position beyond the next twelve months, we are expecting our business opportunities and customer base to continue to expand and grow, which may provide us with additional liquidity to fund our operations. We may consider financing transactions to fund our operations if opportunities arise. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures. Debt financing would also result in fixed payment obligations.

 

On November 7, 2023, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (collectively, the “Investors”) pursuant to which we agreed to sell and issue to the Investors in a private placement transaction (the “Private Placement”) in one or more closings up to an aggregate principal amount of $5,000,000 (the “Notes”). As of November 7, 2023, we issued and sold an aggregate of $2,600,000 of Notes pursuant to the SPA before deducting the placement agent’s fees and other estimated offering expenses. The initial closing of the Private Placement occurred on November 7, 2023.

 

The Notes are due on the fifth anniversary of the issuance date of the Notes and bear simple interest at a rate of 12% per annum, payable in equal monthly installments. The Notes are convertible into shares of our Common Stock, at the option of the holder, at an initial conversion price of $1.25 per share, which shall not exceed $1.55 per share. In addition, we can require Investors to convert the Notes at the then current conversion price at any time after 90 days from the issue date if the Common Stock has a closing bid price of $1.55 per share or higher on any twenty days within a thirty day period of consecutive trading days, or if a “fundamental change” occurs (as defined in the SPA). The Notes are unsecured and senior to other indebtedness subject to certain exceptions.

 

 
53

Table of Contents

 

Critical Accounting Estimates

 

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimation process requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. Actual results could differ materially from our estimates.

 

The SEC defines critical accounting estimates as those that are, in management’s view, most important to the portrayal of our financial condition and results of operations and the most demanding of our judgment. We consider the following estimates to be critical to an understanding of our consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows.

 

Revenue Recognition

 

We recognize revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606). We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations.

 

We must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.

 

Title and risk of loss generally pass to our customers upon shipment. Our customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Shipping and handling costs charged to customers are included in Product Revenues. The associated expenses are treated as fulfillment costs and are included in Cost of Revenues. Revenues are reported net of sales taxes collected from customers.

 

Product revenue includes sales from our standard and customized equipment, solution and accessories sold with our equipment. Revenue is recognized upon transfer of control of promised products to customers in an amount that reflects the consideration we expect to receive in exchange for those products.

 

Service and training revenue include sales from our high-level decontamination and service engagements, validation of our equipment and technology and customer training. Service revenue is recognized as the agreed upon services are rendered to our customers in an amount that reflects the consideration we expect to receive in exchange for those services.

 

 
54

Table of Contents

 

Estimated allowances for sales returns are recorded as sales are recognized. We use a specific identification method based on subsequent product return activity and historical average calculation to estimate the allowance for sales returns.

 

Costs to Obtain a Contract with a Customer

 

We apply a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling expenses.

 

Contract Balances

 

As of September 30, 2024, and December 31, 2023 we did not have any unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

 

Arrangements with Multiple Performance Obligations

 

Our contracts with customers may include multiple performance obligations. We enter into contracts that can include various combinations of products and services, which are primarily distinct and accounted for as separate performance obligations.

 

Significant Judgments

 

Our contracts with customers for products and services often dictate the terms and conditions of when the control of the promised products or services is transferred to the customer and the amount of consideration to be received in exchange for the products and services.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, inventory, fair values of financial instruments, intangible assets, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of our assets and liabilities.

 

 
55

Table of Contents

 

Accounts Receivable

 

Our accounts receivable are typically from credit worthy customers or, for certain international customers, are supported by pre-payments. For those customers to whom we extend credit, we perform periodic evaluations of them and maintain allowances for potential credit losses as deemed necessary. We have a policy of reserving for credit losses based on our best estimate of the amount of potential credit losses in existing accounts receivable. We periodically review our accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

Inventories

 

Inventories are valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventories consist primarily of finished goods. We expense costs to maintain certification to cost of goods sold as incurred.

 

We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories may not be usable.

 

Long-Lived Assets Including Acquired Intangible Assets

 

We assess long-lived assets for potential impairments at the end of each year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the asset. In evaluating long-lived assets for impairment, we measure recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If our long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value. We base the calculations of the estimated fair value of our long-lived assets on the income approach. For the income approach, we use an internally developed discounted cash flow model that includes, among others, the following assumptions: projections of revenues and expenses and related cash flows based on assumed long-term growth rates and demand trends; expected future investments to grow new units; and estimated discount rates. We base these assumptions on our historical data and experience, industry projections, micro and macro general economic condition projections, and our expectations. We had no long-lived asset impairment charges for the three and nine months ended September 30, 2024 and 2023.

 

Recently issued accounting pronouncements not yet adopted

 

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

 

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.

 

 
56

Table of Contents

 

Item 3.Quantitative and Qualitative Disclosures About Market Risk.

 

Not Applicable.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report on Form 10-Q. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) under the Exchange Act during the period covered by this Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

 
57

Table of Contents

 

PART II: OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on the results of our operations, financial position or cash flows. Regardless of the outcome, any litigation could have an adverse impact on us due to defense and settlement costs, diversion of management resources and other factors.

 

Item 1A. Risk Factors.

 

You should carefully consider the information described in the “Risk Factors” section of our Annual Report for the fiscal year ended December 31, 2023, as filed with the SEC on April 1, 2024. There have been no material changes to the risk factors we previously disclosed in our filings with the SEC, including the Annual Report. Our operations could also be affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.

 

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

10b5-1 Arrangements

 

To the best of the Company’s knowledge during the fiscal quarter ended September 30, 2024, no director or officer (as defined in Rule 16a-1(f) of the Securities Exchange Act) of the Company adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements.

 

 
58

Table of Contents

 

Item 6. Exhibits.

 

The documents listed in the Exhibit Index of this Form 10-Q are incorporated herein by reference.

 

 

 
59

Table of Contents

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 

 

 

 

 

Date: October 30, 2024

By:

/s/ HALDEN S. SHANE

 

 

 

Halden S. Shane

 

 

 

Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

Date: October 30, 2024

By:

/s/ JOE RZEPKA

 

 

 

Joe Rzepka

 

 

 

Chief Financial Officer

 

 

 

(Principal Financial Officer and

 

 

 

Principal Accounting Officer)

 

 

 
60

Table of Contents

 

EXHIBIT INDEX

 

Exhibit Number

 

Description of Exhibit

 

Form

 

File No.

 

Date

 

Exhibit

 

Filed Herewith

31.1

 

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

 

X

31.2

 

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

 

X

32.1#

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

 

X

32.2#

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

101.INS

 

XBRL Instance Document

 

 

 

 

 

 

 

 

 

X

101.SCH

 

XBRL Taxonomy Extension Schema

 

 

 

 

 

 

 

 

 

X

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase

 

 

 

 

 

 

 

 

 

X

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase

 

 

 

 

 

 

 

 

 

X

101.LAB

 

XBRL Taxonomy Extension Label Linkbase

 

 

 

 

 

 

 

 

 

X

 

# This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, or the Exchange Act.

 

 
61